Ari D Baron, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 36 years
- Tufts University School of Medicine, 1990
Offices
2 locations · Sutter Bay Medical Foundation · Pacific Hematology Oncology Assoc.
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Mills-Peninsula Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Baron’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G72619 · Current
Licensed to practise in California · since 1991 · expires 2027-07-31 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,447,280
Medicare paid this office $2,447,280 for 584 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 15 | $392,910 | None |
| Injection, nivolumab, 1 mg | 11 | $193,337 | None |
| Injection, denosumab, 1 mg | 50 | $187,867 | None |
| Return visit (30+ min) | 434 | $101,828 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 85 | $61,911 | $136 |
See all 40 services
| Injection, pembrolizumab, 1 mg | 15 | $392,910 | None |
| Injection, nivolumab, 1 mg | 11 | $193,337 | None |
| Injection, denosumab, 1 mg | 50 | $187,867 | None |
| Return visit (30+ min) | 434 | $101,828 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 85 | $61,911 | $136 |
| Long return visit (40+ min) | 164 | $47,902 | $161 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 28 | $47,181 | None |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 19 | $46,613 | $110 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 48 | $25,845 | None |
| Administration of prolonged chemotherapy into vein | 21 | $17,335 | $138 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $15,569 | $68 |
| New patient visit (60+ min) | 56 | $11,325 | $202 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $9,678 | $67 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 200 | $7,374 | $8 |
| Injection of drug or substance under skin or into muscle | 109 | $6,015 | $13 |
| Administration of chemotherapy into vein, each additional hour | 28 | $5,448 | $28 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22 | $5,341 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $5,162 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $5,027 | $35 |
| Injection of additional new drug or substance into vein | 60 | $4,493 | $16 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $4,305 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,195 | $105 |
| Injection, leucovorin calcium, per 50 mg | 19 | $3,992 | None |
| New patient visit (45+ min) | 25 | $3,496 | $140 |
| Drawing of blood for a medical problem | 16 | $3,278 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,909 | $153 |
| Injection, fluorouracil, 500 mg | 23 | $2,400 | None |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $2,217 | $33 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 18 | $1,868 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,566 | $87 |
| Injection, palonosetron hcl, 25 mcg | 54 | $1,506 | None |
| Injection of drug or substance into vein | 21 | $1,350 | $38 |
| Telephone medical discussion with physician, 5-10 minutes | 18 | $1,234 | $54 |
| Application of on-body injector for under skin injection | 15 | $1,060 | $18 |
| Irrigation of implanted venous access drug delivery device | 15 | $1,031 | $26 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $886 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $533 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 55 | $256 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $41 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $27 | None |
Who their Medicare patients are
584 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 21% · Women 46% · Also on Medicaid 22% · Health risk score 1.82. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 72% · Cancer 57% · Diabetes 30% · Coronary heart disease 29% · Chronic kidney disease 28% · Atrial fibrillation 21% · Depression 19% · Heart failure 18% · COPD 14% · Dementia 10% · Stroke 8%.
The office billed $8,838,952, Medicare allowed $3,081,295 and paid $2,447,280; for 143,015 services of 109 kinds; $2,111,811 of it was for drugs given in the office and $335,469 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 584 | 143,015 | 77 | 1.82 | $8,838,952 | $2,447,280 |
| 2023 | 558 | 132,238 | 78 | 1.82 | $9,051,957 | $2,410,783 |
| 2022 | 577 | 139,403 | 77 | 1.74 | $8,883,797 | $2,532,120 |
| 2021 | 510 | 133,850 | 77 | 1.86 | $8,444,694 | $2,374,979 |
| 2020 | 509 | 130,939 | 76 | 1.90 | $8,340,029 | $2,384,567 |
| 2019 | 525 | 152,278 | 75 | 2.00 | $7,137,724 | $1,972,705 |
| 2018 | 500 | 245,014 | 75 | 2.03 | $8,086,632 | $2,364,421 |
| 2017 | 521 | 243,051 | 75 | 1.97 | $7,351,515 | $2,300,616 |
| 2016 | 538 | 193,747 | 75 | 1.99 | $7,616,971 | $2,206,008 |
| 2015 | 467 | 171,328 | 75 | 2.01 | $7,243,680 | $2,091,376 |
| 2014 | 445 | 149,218 | 75 | 1.88 | $7,596,632 | $2,330,008 |
| 2013 | 434 | 165,880 | 74 | 1.75 | $7,045,231 | $2,265,776 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 46 services
| Injection, pembrolizumab, 1 mg | 12 | $457,320 | None |
| Injection, nivolumab, 1 mg | 13 | $147,385 | None |
| Injection, denosumab, 1 mg | 46 | $122,363 | None |
| Return visit (30+ min) | 395 | $84,395 | $108 |
| Administration of chemotherapy into vein, 1 hour or less | 105 | $81,673 | $136 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 46 | $51,935 | None |
| Long return visit (40+ min) | 189 | $49,751 | $156 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 38 | $23,570 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 13 | $19,303 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 46 | $15,860 | $67 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 45 | $11,751 | None |
| Administration of prolonged chemotherapy into vein | 15 | $9,554 | $136 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22 | $9,448 | $0 |
| Telephone medical discussion with physician, 21-30 minutes | 93 | $9,429 | $86 |
| New patient visit (60+ min) | 42 | $8,099 | $193 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 200 | $7,222 | $8 |
| New patient visit (45+ min) | 45 | $6,510 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 58 | $6,510 | $29 |
| Injection of drug or substance under skin or into muscle | 106 | $6,385 | $13 |
| Administration of chemotherapy into vein, each additional hour | 36 | $5,848 | $29 |
| Short return visit (20+ min) | 58 | $5,539 | $74 |
| Injection of additional new drug or substance into vein | 76 | $5,365 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $4,981 | $70 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 50 | $4,518 | $33 |
| Administration of additional new drug or substance into vein using push technique | 17 | $4,386 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,481 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,922 | $154 |
| Injection, leucovorin calcium, per 50 mg | 15 | $2,740 | None |
| Application of on-body injector for under skin injection | 42 | $2,332 | $19 |
| Injection of drug or substance into vein | 29 | $1,893 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,611 | $67 |
| Injection, palonosetron hcl, 25 mcg | 54 | $1,255 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $1,251 | $26 |
| Injection, fluorouracil, 500 mg | 18 | $1,207 | None |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,151 | $34 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $883 | None |
| Injection, fosaprepitant, 1 mg | 17 | $737 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $679 | $20 |
| Injection, oxaliplatin, 0.5 mg | 12 | $474 | None |
| Short return visit | 14 | $464 | $27 |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $302 | None |
| Injection, carboplatin, 50 mg | 16 | $210 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 29 | $88 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $57 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $46 | None |
| Unclassified drugs | 13 | $33 | None |
2022: 51 services
| Injection, pembrolizumab, 1 mg | 18 | $473,109 | None |
| Injection, nivolumab, 1 mg | 17 | $440,785 | None |
| Injection, denosumab, 1 mg | 41 | $159,340 | None |
| Injection, paclitaxel protein-bound particles, 1 mg | 11 | $114,566 | None |
| Administration of chemotherapy into vein, 1 hour or less | 123 | $93,434 | $140 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 41 | $73,302 | None |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 13 | $72,789 | $33 |
| Return visit (30+ min) | 339 | $65,156 | $108 |
| Long return visit (40+ min) | 241 | $64,022 | $147 |
| Administration of additional new drug or substance into vein, 1 hour or less | 57 | $20,063 | $69 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15 | $16,527 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $13,835 | $173 |
| Telephone medical discussion with physician, 21-30 minutes | 113 | $13,643 | $86 |
| New patient visit (60+ min) | 57 | $11,282 | $198 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 70 | $9,720 | $30 |
| Injection of additional new drug or substance into vein | 97 | $9,362 | $16 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $9,109 | $1 |
| Short return visit (20+ min) | 96 | $8,577 | $69 |
| Administration of chemotherapy into vein, each additional hour | 54 | $8,016 | $29 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $7,896 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 205 | $7,232 | $8 |
| Injection of drug or substance under skin or into muscle | 86 | $5,933 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $5,374 | $31 |
| Injection of drug or substance into vein | 46 | $4,845 | $39 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,511 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,254 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,070 | $90 |
| Injection, leucovorin calcium, per 50 mg | 15 | $2,848 | None |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,726 | $58 |
| Application of on-body injector for under skin injection | 40 | $2,503 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $2,032 | $66 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 18 | $1,557 | None |
| Extended patient service without direct patient contact, first hour | 14 | $1,368 | $98 |
| Injection, palonosetron hcl, 25 mcg | 64 | $1,343 | None |
| Injection, fluorouracil, 500 mg | 22 | $1,320 | None |
| Insertion of needle into vein for collection of blood sample | 153 | $1,298 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $1,265 | $19 |
| Short return visit | 23 | $1,156 | $44 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $880 | $35 |
| Injection, oxaliplatin, 0.5 mg | 17 | $583 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $528 | $13 |
| Injection, fosaprepitant, 1 mg | 18 | $485 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $394 | $23 |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $350 | None |
| Injection, carboplatin, 50 mg | 17 | $255 | None |
| Infusion, normal saline solution , 1000 cc | 28 | $187 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 11 | $138 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 39 | $125 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 33 | $71 | None |
| Unclassified drugs | 22 | $50 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $41 | None |
2021: 43 services
| Injection, pembrolizumab, 1 mg | 12 | $348,978 | None |
| Injection, denosumab, 1 mg | 40 | $165,754 | None |
| Injection, pegfilgrastim, 6 mg | 32 | $109,169 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $104,404 | $152 |
| Long return visit (40+ min) | 208 | $68,123 | $163 |
| Return visit (30+ min) | 289 | $56,964 | $114 |
| Injection, bevacizumab, 10 mg | 14 | $25,005 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $22,046 | $74 |
| Short return visit (20+ min) | 123 | $18,067 | $81 |
| New patient visit (60+ min) | 80 | $16,120 | $202 |
| Telephone medical discussion with physician, 21-30 minutes | 95 | $13,464 | $122 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 66 | $12,856 | $32 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $11,952 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 15 | $10,865 | $175 |
| Injection of additional new drug or substance into vein | 75 | $9,778 | $17 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $8,521 | $1 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 177 | $7,273 | $8 |
| Telephone medical discussion with physician, 11-20 minutes | 79 | $7,116 | $84 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 47 | $6,396 | $32 |
| Administration of chemotherapy into vein, each additional hour | 31 | $5,809 | $32 |
| Injection of drug or substance under skin or into muscle | 82 | $5,096 | $13 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,756 | $63 |
| Injection, palonosetron hcl, 25 mcg | 55 | $3,572 | None |
| Application of on-body injector for under skin injection | 30 | $3,213 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,770 | $92 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $2,654 | $74 |
| Injection of drug or substance into vein | 32 | $2,609 | $42 |
| Short return visit | 37 | $2,517 | $47 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $2,140 | $36 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $1,848 | None |
| Insertion of needle into vein for collection of blood sample | 141 | $1,716 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $1,208 | $21 |
| Injection, fluorouracil, 500 mg | 16 | $934 | None |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $706 | $54 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $506 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $493 | None |
| Injection, carboplatin, 50 mg | 15 | $244 | None |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 16 | $178 | $9 |
| Infusion, normal saline solution , 1000 cc | 16 | $162 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $76 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 20 | $72 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 25 | $52 | None |
| Unclassified drugs | 13 | $34 | None |
2020: 47 services
| Injection, pembrolizumab, 1 mg | 16 | $505,372 | None |
| Injection, nivolumab, 1 mg | 12 | $310,305 | None |
| Injection, bevacizumab, 10 mg | 14 | $201,493 | None |
| Injection, denosumab, 1 mg | 32 | $126,835 | None |
| Injection, rituximab, 10 mg | 16 | $115,218 | None |
| Administration of chemotherapy into vein, 1 hour or less | 100 | $91,330 | $146 |
| Injection, pegfilgrastim, 6 mg | 30 | $85,028 | None |
| Long return visit (40+ min) | 216 | $64,969 | $135 |
| Return visit (30+ min) | 361 | $59,847 | $96 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $20,618 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 35 | $16,773 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $15,739 | $72 |
| Short return visit (20+ min) | 116 | $14,168 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $11,544 | $31 |
| New patient visit (60+ min) | 52 | $9,866 | $190 |
| Administration of prolonged chemotherapy into vein | 11 | $8,389 | $150 |
| Injection of additional new drug or substance into vein | 71 | $7,493 | $16 |
| Injection, palonosetron hcl, 25 mcg | 50 | $6,908 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 181 | $6,569 | $8 |
| Administration of chemotherapy into vein, each additional hour | 38 | $5,447 | $31 |
| New patient visit (45+ min) | 37 | $5,447 | $147 |
| Telephone medical discussion with physician, 21-30 minutes | 37 | $5,021 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $4,742 | $31 |
| Injection of drug or substance under skin or into muscle | 85 | $4,344 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $4,193 | $95 |
| Extended patient service without direct patient contact, first hour | 31 | $3,720 | $103 |
| Administration of additional new drug or substance into vein using push technique | 12 | $3,383 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,754 | $66 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 23 | $2,506 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $2,226 | $74 |
| Injection of drug or substance into vein | 23 | $2,180 | $40 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,683 | $62 |
| Telephone medical discussion with physician, 5-10 minutes | 28 | $1,530 | $43 |
| Insertion of needle into vein for collection of blood sample | 137 | $1,392 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $1,389 | $21 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,258 | $31 |
| Application of on-body injector for under skin injection | 25 | $1,215 | $20 |
| Short return visit | 17 | $870 | $44 |
| Injection, fluorouracil, 500 mg | 16 | $723 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $467 | None |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 24 | $434 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $346 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $307 | $20 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 27 | $224 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $87 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $61 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $34 | None |
2019: 43 services
| Injection, pembrolizumab, 1 mg | 13 | $294,348 | None |
| Injection, denosumab, 1 mg | 33 | $99,942 | None |
| Administration of chemotherapy into vein, 1 hour or less | 88 | $71,111 | $142 |
| Injection, pegfilgrastim, 6 mg | 20 | $57,673 | None |
| Return visit (30+ min) | 326 | $53,420 | $93 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14 | $42,020 | None |
| Long return visit (40+ min) | 149 | $41,915 | $132 |
| Injection, palonosetron hcl, 25 mcg | 49 | $16,833 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $15,315 | $65 |
| Short return visit (20+ min) | 128 | $12,452 | $66 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $11,447 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 60 | $11,206 | $31 |
| Other chemotherapy procedure | 18 | $10,799 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $9,105 | $93 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $8,625 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 200 | $8,130 | $8 |
| Injection, fosaprepitant, 1 mg | 13 | $7,349 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 12 | $6,758 | None |
| Extended patient service without direct patient contact, first hour | 58 | $6,733 | $92 |
| Injection of additional new drug or substance into vein | 74 | $6,503 | $17 |
| New patient visit (45+ min) | 41 | $5,932 | $145 |
| New patient visit (60+ min) | 31 | $5,919 | $191 |
| Injection of drug or substance under skin or into muscle | 73 | $4,827 | $15 |
| Administration of chemotherapy into vein, each additional hour | 34 | $4,605 | $31 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,805 | $181 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $3,177 | $30 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 19 | $2,803 | None |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $2,756 | $39 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,292 | $60 |
| Injection of drug or substance into vein | 32 | $1,944 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,925 | $74 |
| Injection, oxaliplatin, 0.5 mg | 11 | $1,712 | None |
| Insertion of needle into vein for collection of blood sample | 115 | $1,035 | $3 |
| Application of on-body injector for under skin injection | 18 | $946 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $898 | $21 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 28 | $752 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $671 | $18 |
| Injection, fluorouracil, 500 mg | 21 | $472 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $303 | None |
| Infusion, normal saline solution , 1000 cc | 24 | $197 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $50 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $46 | None |
| Unclassified drugs | 16 | $44 | None |
2018: 48 services
| Injection, bevacizumab, 10 mg | 15 | $392,785 | None |
| Injection, nivolumab, 1 mg | 11 | $347,701 | None |
| Injection, rituximab, 100 mg | 16 | $211,305 | None |
| Injection, denosumab, 1 mg | 31 | $95,423 | None |
| Administration of chemotherapy into vein, 1 hour or less | 93 | $86,248 | $145 |
| Return visit (30+ min) | 332 | $55,908 | $93 |
| Injection, palonosetron hcl, 25 mcg | 56 | $51,318 | None |
| Injection, pegfilgrastim, 6 mg | 21 | $49,862 | None |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 20 | $26,707 | None |
| Long return visit (40+ min) | 110 | $24,997 | $129 |
| Other chemotherapy procedure | 25 | $22,092 | $165 |
| Short return visit (20+ min) | 172 | $18,585 | $61 |
| Administration of additional new drug or substance into vein, 1 hour or less | 43 | $15,748 | $70 |
| Injection, fosaprepitant, 1 mg | 17 | $15,502 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $15,100 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $13,986 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $12,483 | $65 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 182 | $8,676 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $8,155 | None |
| Injection of additional new drug or substance into vein | 77 | $7,842 | $18 |
| New patient visit (45+ min) | 52 | $7,558 | $145 |
| Administration of chemotherapy into vein, each additional hour | 46 | $7,143 | $31 |
| Injection of drug or substance under skin or into muscle | 69 | $6,413 | $20 |
| Administration of additional new drug or substance into vein using push technique | 26 | $5,810 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,474 | $160 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $3,764 | $46 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $3,750 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $3,748 | None |
| New patient visit (60+ min) | 22 | $3,584 | $163 |
| Injection, irinotecan, 20 mg | 13 | $2,625 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $2,228 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $2,001 | $21 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,888 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,703 | $66 |
| Application of on-body injector for under skin injection | 19 | $1,437 | $20 |
| Injection of drug or substance into vein | 22 | $1,322 | $46 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,189 | $66 |
| Insertion of needle into vein for collection of blood sample | 116 | $1,100 | $3 |
| Injection, fluorouracil, 500 mg | 28 | $672 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 31 | $640 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $495 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $328 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $288 | $13 |
| Injection, atropine sulfate, 0.01 mg | 14 | $283 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $173 | None |
| Unclassified drugs | 18 | $102 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 35 | $45 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $16 | None |
2017: 47 services
| Injection, bevacizumab, 10 mg | 23 | $592,177 | None |
| Injection, rituximab, 100 mg | 11 | $163,254 | None |
| Injection, nivolumab, 1 mg | 11 | $139,506 | None |
| Injection, denosumab, 1 mg | 25 | $87,330 | None |
| Administration of chemotherapy into vein, 1 hour or less | 84 | $75,342 | $141 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 18 | $67,824 | None |
| Return visit (30+ min) | 327 | $58,100 | $90 |
| Injection, palonosetron hcl, 25 mcg | 51 | $57,387 | None |
| Injection, pegfilgrastim, 6 mg | 22 | $46,585 | None |
| Other chemotherapy procedure | 21 | $27,237 | $163 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $22,607 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $20,653 | $65 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $16,215 | $68 |
| Short return visit (20+ min) | 143 | $13,835 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $12,793 | $31 |
| Long return visit (40+ min) | 69 | $12,440 | $132 |
| Injection, fosaprepitant, 1 mg | 15 | $11,635 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 200 | $11,014 | $10 |
| Injection of drug or substance under skin or into muscle | 69 | $10,835 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $9,887 | $93 |
| Injection of additional new drug or substance into vein | 69 | $9,273 | $23 |
| New patient visit (45+ min) | 57 | $8,476 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,877 | $175 |
| Administration of chemotherapy into vein, each additional hour | 34 | $5,706 | $29 |
| Administration of additional new drug or substance into vein using push technique | 24 | $5,684 | $65 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $4,982 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $4,881 | None |
| New patient visit (60+ min) | 25 | $4,467 | $179 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 57 | $3,616 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $3,066 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,845 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,938 | $69 |
| Aspiration of bone marrow sample for diagnosis | 11 | $1,867 | $170 |
| Hospital discharge day management, 30 minutes or less | 26 | $1,825 | $65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,613 | $30 |
| Injection, fluorouracil, 500 mg | 27 | $1,410 | None |
| Injection, leucovorin calcium, per 50 mg | 11 | $1,233 | None |
| Injection, carboplatin, 50 mg | 15 | $946 | None |
| Biopsy of bone marrow | 11 | $887 | $81 |
| Insertion of needle into vein for collection of blood sample | 99 | $835 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 25 | $559 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 58 | $313 | None |
| Blood test, clotting time | 12 | $211 | $5 |
| Infusion, normal saline solution , 1000 cc | 21 | $102 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $40 | None |
| Unclassified drugs | 17 | $38 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $32 | None |
2016: 47 services
| Injection, bevacizumab, 10 mg | 14 | $250,263 | None |
| Injection, pegfilgrastim, 6 mg | 35 | $244,408 | None |
| Injection, rituximab, 100 mg | 12 | $164,409 | None |
| Injection, denosumab, 1 mg | 24 | $142,472 | None |
| Injection, nivolumab, 1 mg | 11 | $106,960 | None |
| Return visit (30+ min) | 374 | $75,096 | $94 |
| Administration of chemotherapy into vein, 1 hour or less | 84 | $60,534 | $141 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16 | $43,022 | None |
| Injection, palonosetron hcl, 25 mcg | 51 | $36,843 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $34,156 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $14,067 | $93 |
| New patient visit (45+ min) | 84 | $12,675 | $151 |
| Short return visit (20+ min) | 129 | $12,591 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $11,872 | $76 |
| Long return visit (40+ min) | 54 | $11,524 | $131 |
| Injection, fosaprepitant, 1 mg | 11 | $10,931 | None |
| Injection, docetaxel, 1 mg | 12 | $10,767 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 227 | $10,671 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $10,467 | $31 |
| Injection of drug or substance under skin or into muscle | 84 | $9,283 | $25 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $8,207 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $8,148 | $66 |
| Injection of additional new drug or substance into vein | 70 | $7,494 | $23 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,377 | $180 |
| Administration of chemotherapy into vein, each additional hour | 32 | $6,467 | $29 |
| Injection of drug or substance into vein | 27 | $6,152 | $55 |
| Biopsy of bone marrow | 18 | $3,425 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $3,242 | $105 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 16 | $3,045 | None |
| New patient visit (60+ min) | 16 | $2,937 | $184 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $2,193 | $73 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,028 | $65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,850 | $31 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,764 | $65 |
| Aspiration of bone marrow sample for diagnosis | 18 | $1,693 | $85 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 33 | $1,398 | $19 |
| Injection, fluorouracil, 500 mg | 12 | $1,250 | None |
| Insertion of needle into vein for collection of blood sample | 120 | $947 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 25 | $626 | None |
| Injection, carboplatin, 50 mg | 12 | $602 | None |
| Unclassified drugs | 26 | $504 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $279 | None |
| Blood test, clotting time | 16 | $231 | $5 |
| Infusion, normal saline solution , 1000 cc | 12 | $53 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $40 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $20 | None |
| Injection, midazolam hydrochloride, per 1 mg | 18 | $11 | None |
2015: 40 services
| Injection, pegfilgrastim, 6 mg | 20 | $186,224 | None |
| Injection, denosumab, 1 mg | 18 | $133,527 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18 | $76,546 | None |
| Return visit (30+ min) | 317 | $69,114 | $97 |
| Administration of chemotherapy into vein, 1 hour or less | 52 | $66,230 | $142 |
| Injection, palonosetron hcl, 25 mcg | 37 | $53,148 | None |
| Short return visit (20+ min) | 183 | $31,267 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $26,916 | $65 |
| Long return visit (40+ min) | 102 | $20,464 | $130 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $18,688 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $18,540 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 41 | $13,305 | $31 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 159 | $12,620 | $10 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $11,823 | $66 |
| Administration of prolonged chemotherapy into vein | 11 | $11,433 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $9,081 | $94 |
| Injection of drug or substance into vein | 29 | $8,586 | $58 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $8,103 | None |
| New patient visit (45+ min) | 54 | $7,846 | $145 |
| Injection of additional new drug or substance into vein | 39 | $7,313 | $23 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,977 | $174 |
| New patient visit (60+ min) | 36 | $6,926 | $192 |
| Not otherwise classified, antineoplastic drugs | 11 | $6,376 | None |
| Injection of drug or substance under skin or into muscle | 41 | $5,153 | $25 |
| Biopsy of bone marrow | 23 | $4,623 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $4,289 | $116 |
| Refilling and maintenance of portable pump | 13 | $3,726 | $143 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 55 | $3,365 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $3,325 | $33 |
| Administration of chemotherapy into vein, each additional hour | 18 | $3,307 | $29 |
| Aspiration of bone marrow sample for diagnosis | 23 | $2,284 | $85 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 34 | $2,147 | None |
| Hospital discharge day management, 30 minutes or less | 27 | $1,940 | $67 |
| Insertion of needle into vein for collection of blood sample | 108 | $1,105 | $3 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,096 | $58 |
| Injection, fluorouracil, 500 mg | 12 | $1,005 | None |
| Unclassified drugs | 26 | $506 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $389 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $20 | None |
| Injection, midazolam hydrochloride, per 1 mg | 20 | $12 | None |
2014: 46 services
| Injection, bevacizumab, 10 mg | 15 | $455,133 | None |
| Injection, denosumab, 1 mg | 23 | $173,353 | None |
| Injection, pegfilgrastim, 6 mg | 11 | $127,573 | None |
| Return visit (30+ min) | 333 | $84,876 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $60,722 | $138 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $60,328 | None |
| Injection, palonosetron hcl, 25 mcg | 35 | $45,699 | None |
| Short return visit (20+ min) | 162 | $35,397 | $65 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $23,497 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $21,466 | $64 |
| Refilling and maintenance of portable pump | 24 | $18,176 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 44 | $16,298 | $31 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $14,458 | $75 |
| Administration of prolonged chemotherapy into vein | 14 | $13,572 | $138 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $13,495 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 133 | $12,958 | $10 |
| New patient visit (45+ min) | 65 | $9,530 | $147 |
| Injection of additional new drug or substance into vein | 45 | $9,156 | $23 |
| Administration of additional new drug or substance into vein using push technique | 16 | $8,517 | $64 |
| Injection of drug or substance into vein | 32 | $7,392 | $56 |
| Injection of drug or substance under skin or into muscle | 38 | $6,644 | $25 |
| Injection, leucovorin calcium, per 50 mg | 11 | $6,329 | None |
| Long return visit (40+ min) | 34 | $5,692 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $5,569 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,566 | $169 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 64 | $5,282 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $5,083 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $4,929 | $117 |
| Administration of chemotherapy into vein, each additional hour | 21 | $4,550 | $28 |
| New patient visit (60+ min) | 20 | $3,685 | $184 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $3,348 | $32 |
| Drawing of blood for a medical problem | 11 | $3,094 | $100 |
| Hospital discharge day management, 30 minutes or less | 27 | $2,833 | $66 |
| Biopsy of bone marrow | 12 | $2,340 | $167 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 30 | $1,969 | None |
| Injection, fluorouracil, 500 mg | 18 | $1,473 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $1,246 | $15 |
| Aspiration of bone marrow sample for diagnosis | 12 | $1,138 | $81 |
| Insertion of needle into vein for collection of blood sample | 84 | $850 | $3 |
| Short return visit | 13 | $547 | $36 |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $374 | None |
| Unclassified drugs | 17 | $172 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $35 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $32 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $27 | None |
| Injection, midazolam hydrochloride, per 1 mg | 12 | $7 | None |
2013: 40 services
| Injection, bevacizumab, 10 mg | 14 | $530,430 | None |
| Injection, pegfilgrastim, 6 mg | 24 | $238,168 | None |
| Injection, denosumab, 1 mg | 23 | $224,229 | None |
| Return visit (30+ min) | 318 | $88,026 | $92 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16 | $71,791 | None |
| Administration of chemotherapy into vein, 1 hour or less | 47 | $61,107 | $149 |
| Injection, palonosetron hcl, 25 mcg | 37 | $36,811 | None |
| Refilling and maintenance of portable pump | 22 | $35,818 | $148 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $34,397 | None |
| Short return visit (20+ min) | 154 | $30,042 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $18,827 | $63 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $18,779 | $78 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $13,510 | $74 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 127 | $11,132 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 42 | $10,810 | $33 |
| New patient visit (45+ min) | 66 | $9,478 | $144 |
| Injection of additional new drug or substance into vein | 50 | $8,218 | $23 |
| Injection of drug or substance under skin or into muscle | 49 | $8,199 | $26 |
| Long return visit (40+ min) | 36 | $6,742 | $127 |
| Injection of drug or substance into vein | 23 | $6,703 | $59 |
| Administration of additional new drug or substance into vein using push technique | 15 | $5,904 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 68 | $5,728 | $20 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,720 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,231 | $176 |
| Administration of chemotherapy into vein, each additional hour | 22 | $4,230 | $31 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $2,950 | $32 |
| New patient visit (60+ min) | 15 | $2,689 | $179 |
| Hospital discharge day management, 30 minutes or less | 32 | $2,380 | $64 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 28 | $1,555 | None |
| Injection, fluorouracil, 500 mg | 16 | $1,548 | None |
| Injection, carboplatin, 50 mg | 14 | $1,076 | None |
| Short return visit | 18 | $802 | $42 |
| Blood test, clotting time | 11 | $568 | $5 |
| Insertion of needle into vein for collection of blood sample | 59 | $407 | $3 |
| Infusion into a vein for hydration, each additional hour | 14 | $279 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $274 | None |
| Unclassified drugs | 16 | $74 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $46 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $29 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $18 | None |
Medicaid work
$14,452 in 2024
Medicaid paid $14,452 for 536 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 202 | $11,636 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 264 | $1,270 |
| Long return visit (40+ min) | 13 | $755 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 41 | $561 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 16 | $230 |
| 2024 | 536 | 5 | 39 | $14,452 |
| 2023 | 577 | 4 | 27 | $13,694 |
| 2022 | 382 | 5 | 22 | $2,046 |
| 2021 | 224 | 3 | 24 | $1,104 |
| 2020 | 163 | 2 | 19 | $923 |
| 2019 | 162 | 2 | 16 | $2,198 |
| 2018 | 70 | 1 | 16 | $27 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 129 | $5,665 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 102 | $3,869 |
| Long return visit (40+ min) | 19 | $2,524 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 327 | $1,636 |
2022
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 244 | $824 |
| Return visit (30+ min) | 29 | $694 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 31 | $350 |
| Long return visit (40+ min) | 15 | $160 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 63 | $18 |
2021
| Return visit (30+ min) | 28 | $760 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 148 | $345 |
| Puncture of skin for collection of blood sample | 48 | $0 |
2020
| Return visit (30+ min) | 49 | $614 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 114 | $310 |
2019
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 146 | $1,980 |
| Return visit (30+ min) | 16 | $218 |
2018
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 70 | $27 |
Drugs they prescribed that Part D paid
$16,390,699
Pharmacies billed $16,390,699 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,006 generic and 1,745 brand-name prescriptions · $16,390,699 in drug cost · 42 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nubeqa | 398 | $5,280,039 | $13,266 |
| Lupron Depot | 133 | $809,746 | $6,088 |
| Keytruda | 69 | $773,826 | $11,215 |
| Revlimid | 34 | $647,896 | $19,056 |
| Lynparza | 38 | $622,037 | $16,369 |
See all 55 drugs
| Nubeqa | 398 | $5,280,039 | $13,266 |
| Lupron Depot | 133 | $809,746 | $6,088 |
| Keytruda | 69 | $773,826 | $11,215 |
| Revlimid | 34 | $647,896 | $19,056 |
| Lynparza | 38 | $622,037 | $16,369 |
| Xtandi | 54 | $600,150 | $11,114 |
| Tagrisso | 33 | $582,919 | $17,664 |
| Brukinsa | 34 | $511,426 | $15,042 |
| Ojjaara | 17 | $468,779 | $27,575 |
| Idhifa | 13 | $433,090 | $33,315 |
| Imbruvica | 22 | $373,093 | $16,959 |
| Xgeva | 110 | $348,651 | $3,170 |
| Neulasta Onpro | 53 | $328,705 | $6,202 |
| Zejula | 16 | $296,673 | $18,542 |
| Opdivo | 26 | $296,227 | $11,393 |
| Darzalex Faspro | 14 | $260,289 | $18,592 |
| Jakafi | 11 | $206,759 | $18,796 |
| Venclexta | 16 | $201,396 | $12,587 |
| Verzenio | 11 | $185,426 | $16,857 |
| Abiraterone Acetate | 113 | $184,771 | $1,635 |
| Aranesp | 68 | $154,381 | $2,270 |
| Nplate | 51 | $142,680 | $2,798 |
| Promacta | 12 | $139,229 | $11,602 |
| Gleevec | 13 | $132,664 | $10,205 |
| Zytiga | 12 | $131,041 | $10,920 |
| Somatuline Depot | 13 | $121,893 | $9,376 |
| Eliquis | 164 | $109,727 | $669 |
| Orgovyx | 35 | $91,910 | $2,626 |
| Erleada | 11 | $91,445 | $8,313 |
| Sorafenib | 14 | $84,372 | $6,027 |
| Udenyca | 12 | $48,854 | $4,071 |
| Zirabev | 14 | $45,316 | $3,237 |
| Vemlidy | 27 | $38,553 | $1,428 |
| Creon | 18 | $27,797 | $1,544 |
| Xarelto | 27 | $27,189 | $1,007 |
| Docetaxel | 31 | $9,242 | $298 |
| Bortezomib | 20 | $5,706 | $285 |
| Leucovorin | 43 | $5,600 | $130 |
| Myrbetriq | 12 | $5,413 | $451 |
| Imatinib Mesylate | 28 | $2,899 | $104 |
| Oxaliplatin | 24 | $1,973 | $82 |
| Hydroxyurea | 102 | $1,836 | $18 |
| Anagrelide | 11 | $1,795 | $163 |
| Acyclovir | 78 | $1,355 | $17 |
| Palonosetron | 41 | $1,237 | $30 |
| Gemcitabine | 14 | $988 | $71 |
| Fluorouracil | 11 | $809 | $74 |
| Letrozole | 31 | $707 | $23 |
| Prednisone | 138 | $655 | $5 |
| Prochlorperazine Maleate | 29 | $520 | $18 |
| Anastrozole | 24 | $432 | $18 |
| Dexamethasone | 22 | $409 | $19 |
| Warfarin | 19 | $369 | $19 |
| Tamoxifen Citrate | 26 | $323 | $12 |
| Sulfamethoxazole-Trimethoprim | 38 | $170 | $4 |
Year by year
| 2024 | 2,751 | 274 | None | 63% | $16,390,699 |
| 2023 | 3,432 | 307 | 1% (18) | 59% | $19,686,991 |
| 2022 | 4,023 | 314 | 0% (13) | 52% | $19,676,944 |
| 2021 | 4,450 | 292 | 0% (11) | 46% | $17,520,499 |
| 2020 | 3,852 | 290 | 1% (20) | None | $13,105,074 |
| 2019 | 3,315 | 281 | 2% (74) | 51% | $11,822,332 |
| 2018 | 2,629 | 263 | 2% (60) | None | $8,042,474 |
| 2017 | 2,577 | 249 | 4% (89) | None | $5,958,049 |
| 2016 | 2,082 | 229 | 3% (61) | 40% | $4,401,027 |
| 2015 | 1,766 | 226 | 3% (54) | 45% | $3,986,422 |
| 2014 | 1,652 | 204 | 5% (81) | 36% | $2,980,341 |
| 2013 | 1,327 | 173 | 6% (85) | None | $1,905,967 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 62 drugs
| Nubeqa | 335 | $4,614,784 | $13,775 |
| Opdivo | 100 | $1,175,135 | $11,751 |
| Lupron Depot | 152 | $969,359 | $6,377 |
| Keytruda | 78 | $933,668 | $11,970 |
| Revlimid | 45 | $926,696 | $20,593 |
| Lynparza | 42 | $747,018 | $17,786 |
| Neulasta Onpro | 108 | $741,042 | $6,862 |
| Darzalex Faspro | 37 | $664,105 | $17,949 |
| Jakafi | 20 | $636,752 | $31,838 |
| Xtandi | 49 | $595,503 | $12,153 |
| Pomalyst | 25 | $567,352 | $22,694 |
| Xgeva | 175 | $543,271 | $3,104 |
| Imbruvica | 33 | $541,380 | $16,405 |
| Idhifa | 11 | $372,446 | $33,859 |
| Somatuline Depot | 36 | $368,926 | $10,248 |
| Abiraterone Acetate | 169 | $349,398 | $2,067 |
| Cabometyx | 12 | $332,330 | $27,694 |
| Aranesp | 121 | $329,483 | $2,723 |
| Yervoy | 14 | $251,278 | $17,948 |
| Nplate | 39 | $244,564 | $6,271 |
| Tecentriq | 19 | $210,489 | $11,078 |
| Ruxience | 15 | $201,361 | $13,424 |
| Zirabev | 37 | $200,469 | $5,418 |
| Tagrisso | 14 | $159,822 | $11,416 |
| Imfinzi | 16 | $159,150 | $9,947 |
| Reblozyl | 13 | $156,852 | $12,066 |
| Sorafenib | 12 | $98,596 | $8,216 |
| Eliquis | 127 | $93,066 | $733 |
| Orgovyx | 31 | $85,582 | $2,761 |
| Rituxan | 11 | $66,972 | $6,088 |
| Xarelto | 33 | $31,773 | $963 |
| Doxorubicin Hcl Liposome | 13 | $30,237 | $2,326 |
| Vemlidy | 20 | $29,905 | $1,495 |
| Creon | 17 | $24,563 | $1,445 |
| Prolia | 13 | $22,469 | $1,728 |
| Akynzeo | 21 | $16,810 | $800 |
| Fulvestrant | 20 | $15,470 | $774 |
| Imatinib Mesylate | 27 | $13,609 | $504 |
| Docetaxel | 31 | $11,642 | $376 |
| Leucovorin | 44 | $9,442 | $215 |
| Gemcitabine | 58 | $6,817 | $118 |
| Palonosetron | 101 | $6,030 | $60 |
| Fosaprepitant Dimeglumine | 19 | $5,232 | $275 |
| Anagrelide | 13 | $4,627 | $356 |
| Oxaliplatin | 24 | $4,357 | $182 |
| Hydroxyurea | 100 | $3,499 | $35 |
| Acyclovir | 106 | $2,257 | $21 |
| Prednisone | 181 | $1,696 | $9 |
| Letrozole | 29 | $1,455 | $50 |
| Anastrozole | 37 | $1,186 | $32 |
| Carboplatin | 25 | $1,088 | $44 |
| Bicalutamide | 11 | $743 | $68 |
| Etoposide | 13 | $643 | $49 |
| Prochlorperazine Maleate | 39 | $611 | $16 |
| Tamoxifen Citrate | 27 | $589 | $22 |
| Warfarin | 21 | $495 | $24 |
| Dexamethasone | 32 | $451 | $14 |
| Sulfamethoxazole-Trimethoprim | 53 | $432 | $8 |
| Hydrocortisone | 14 | $419 | $30 |
| Ondansetron Odt | 14 | $343 | $25 |
| Ondansetron | 15 | $214 | $14 |
| Potassium Chloride | 11 | $153 | $14 |
2022: 71 drugs
| Nubeqa | 197 | $2,510,182 | $12,742 |
| Revlimid | 74 | $1,474,772 | $19,929 |
| Neulasta Onpro | 193 | $1,317,628 | $6,827 |
| Opdivo | 77 | $937,598 | $12,177 |
| Lynparza | 61 | $931,009 | $15,262 |
| Lupron Depot | 140 | $869,386 | $6,210 |
| Keytruda | 75 | $850,051 | $11,334 |
| Imbruvica | 66 | $845,650 | $12,813 |
| Cabometyx | 28 | $676,040 | $24,144 |
| Reblozyl | 37 | $607,233 | $16,412 |
| Verzenio | 39 | $584,535 | $14,988 |
| Abiraterone Acetate | 254 | $572,156 | $2,253 |
| Xtandi | 48 | $566,278 | $11,797 |
| Pomalyst | 22 | $437,119 | $19,869 |
| Xgeva | 137 | $389,714 | $2,845 |
| Somatuline Depot | 38 | $383,832 | $10,101 |
| Tibsovo | 12 | $364,989 | $30,416 |
| Idhifa | 11 | $347,416 | $31,583 |
| Aranesp | 135 | $336,211 | $2,490 |
| Avastin | 51 | $327,223 | $6,416 |
| Tecentriq | 31 | $319,455 | $10,305 |
| Jakafi | 13 | $306,258 | $23,558 |
| Lenvima | 12 | $279,318 | $23,276 |
| Copiktra | 13 | $251,670 | $19,359 |
| Venclexta | 22 | $244,522 | $11,115 |
| Yervoy | 13 | $231,187 | $17,784 |
| Tagrisso | 11 | $190,531 | $17,321 |
| Rituxan | 21 | $186,043 | $8,859 |
| Abraxane | 24 | $160,056 | $6,669 |
| Zirabev | 26 | $157,235 | $6,048 |
| Ruxience | 12 | $151,806 | $12,651 |
| Herceptin | 15 | $135,133 | $9,009 |
| Gazyva | 12 | $123,865 | $10,322 |
| Imatinib Mesylate | 48 | $65,789 | $1,371 |
| Eliquis | 80 | $54,584 | $682 |
| Fulvestrant | 60 | $53,015 | $884 |
| Nplate | 14 | $49,412 | $3,529 |
| Creon | 41 | $46,466 | $1,133 |
| Xarelto | 43 | $37,569 | $874 |
| Docetaxel | 20 | $18,982 | $949 |
| Akynzeo | 19 | $15,339 | $807 |
| Fosaprepitant Dimeglumine | 48 | $13,488 | $281 |
| Gemcitabine | 81 | $13,226 | $163 |
| Irinotecan | 29 | $12,011 | $414 |
| Oxaliplatin | 33 | $10,631 | $322 |
| Levoleucovorin | 33 | $10,092 | $306 |
| Palonosetron | 145 | $7,335 | $51 |
| Myrbetriq | 12 | $5,543 | $462 |
| Leucovorin | 25 | $4,697 | $188 |
| Hydroxyurea | 102 | $3,129 | $31 |
| Letrozole | 51 | $1,946 | $38 |
| Acyclovir | 94 | $1,722 | $18 |
| Prednisone | 260 | $1,702 | $7 |
| Paclitaxel | 21 | $1,692 | $81 |
| Carboplatin | 35 | $1,519 | $43 |
| Anastrozole | 39 | $1,310 | $34 |
| Bicalutamide | 19 | $1,216 | $64 |
| Tamoxifen Citrate | 42 | $1,038 | $25 |
| Ondansetron Odt | 17 | $832 | $49 |
| Dexamethasone | 66 | $730 | $11 |
| Megestrol Acetate | 14 | $677 | $48 |
| Sulfamethoxazole-Trimethoprim | 79 | $626 | $8 |
| Ondansetron | 29 | $520 | $18 |
| Hydrocortisone | 12 | $384 | $32 |
| Warfarin | 19 | $384 | $20 |
| Prochlorperazine Maleate | 28 | $335 | $12 |
| Alendronate | 18 | $228 | $13 |
| Potassium Chloride | 17 | $194 | $11 |
| Furosemide | 31 | $138 | $4 |
| Venlafaxine Hcl Er | 12 | $131 | $11 |
| Gabapentin | 17 | $125 | $7 |
2021: 77 drugs
| Neulasta Onpro | 239 | $1,575,725 | $6,593 |
| Revlimid | 83 | $1,546,020 | $18,627 |
| Imbruvica | 96 | $1,190,056 | $12,396 |
| Nubeqa | 80 | $931,796 | $11,647 |
| Cabometyx | 40 | $897,351 | $22,434 |
| Verzenio | 62 | $891,529 | $14,379 |
| Xtandi | 74 | $793,240 | $10,719 |
| Lupron Depot | 134 | $774,734 | $5,782 |
| Keytruda | 58 | $673,597 | $11,614 |
| Abiraterone Acetate | 279 | $576,857 | $2,068 |
| Opdivo | 38 | $505,530 | $13,303 |
| Pomalyst | 26 | $499,240 | $19,202 |
| Avastin | 84 | $483,710 | $5,758 |
| Abraxane | 66 | $446,488 | $6,765 |
| Tecentriq | 39 | $429,555 | $11,014 |
| Somatuline Depot | 40 | $388,234 | $9,706 |
| Tibsovo | 12 | $342,391 | $28,533 |
| Xgeva | 129 | $337,310 | $2,615 |
| Aranesp | 127 | $327,842 | $2,581 |
| Lynparza | 24 | $321,402 | $13,392 |
| Tagrisso | 17 | $276,908 | $16,289 |
| Lenvima | 12 | $253,764 | $21,147 |
| Rituxan | 28 | $230,422 | $8,229 |
| Imatinib Mesylate | 58 | $164,664 | $2,839 |
| Enhertu | 11 | $161,036 | $14,640 |
| Erbitux | 28 | $157,395 | $5,621 |
| Venclexta | 13 | $130,531 | $10,041 |
| Alimta | 18 | $116,431 | $6,468 |
| Sutent | 17 | $111,818 | $6,578 |
| Empliciti | 13 | $101,371 | $7,798 |
| Bendeka | 13 | $77,925 | $5,994 |
| Levoleucovorin | 88 | $70,746 | $804 |
| Fulvestrant | 64 | $64,092 | $1,001 |
| Eliquis | 100 | $63,830 | $638 |
| Gleevec | 12 | $53,402 | $4,450 |
| Nplate | 11 | $47,233 | $4,294 |
| Doxorubicin Hcl Liposome | 22 | $40,486 | $1,840 |
| Creon | 48 | $37,167 | $774 |
| Xarelto | 42 | $34,601 | $824 |
| Palonosetron | 215 | $26,753 | $124 |
| Akynzeo | 33 | $25,403 | $770 |
| Irinotecan | 65 | $13,547 | $208 |
| Gemcitabine | 59 | $9,185 | $156 |
| Myrbetriq | 12 | $5,126 | $427 |
| Anagrelide | 15 | $4,219 | $281 |
| Oxaliplatin | 21 | $3,801 | $181 |
| Hydroxyurea | 87 | $2,761 | $32 |
| Fosaprepitant Dimeglumine | 13 | $2,745 | $211 |
| Paclitaxel | 35 | $2,651 | $76 |
| Carboplatin | 51 | $2,136 | $42 |
| Acyclovir | 124 | $1,992 | $16 |
| Prednisone | 299 | $1,950 | $7 |
| Letrozole | 53 | $1,258 | $24 |
| Bicalutamide | 23 | $1,225 | $53 |
| Tamoxifen Citrate | 35 | $1,192 | $34 |
| Dexamethasone | 88 | $1,135 | $13 |
| Ondansetron | 71 | $1,127 | $16 |
| Dapsone | 11 | $1,018 | $93 |
| Megestrol Acetate | 23 | $977 | $42 |
| Prochlorperazine Maleate | 67 | $939 | $14 |
| Anastrozole | 16 | $872 | $55 |
| Doxycycline Hyclate | 14 | $741 | $53 |
| Sulfamethoxazole-Trimethoprim | 97 | $546 | $6 |
| Warfarin | 21 | $371 | $18 |
| Triamcinolone Acetonide | 13 | $292 | $22 |
| Alendronate | 14 | $284 | $20 |
| Potassium Chloride | 15 | $284 | $19 |
| Hydrocortisone | 13 | $258 | $20 |
| Tamsulosin | 12 | $232 | $19 |
| Lisinopril | 20 | $179 | $9 |
| Gabapentin | 24 | $145 | $6 |
| Mirtazapine | 12 | $134 | $11 |
| Venlafaxine Hcl Er | 13 | $114 | $9 |
| Omeprazole | 12 | $113 | $9 |
| Furosemide | 25 | $101 | $4 |
| Ciprofloxacin | 11 | $93 | $8 |
| Sertraline | 15 | $87 | $6 |
2020: 75 drugs
| Imbruvica | 98 | $1,185,382 | $12,096 |
| Revlimid | 58 | $971,964 | $16,758 |
| Abiraterone Acetate | 262 | $956,422 | $3,650 |
| Opdivo | 74 | $824,878 | $11,147 |
| Neulasta Onpro | 98 | $634,564 | $6,475 |
| Xtandi | 62 | $579,031 | $9,339 |
| Xgeva | 214 | $518,427 | $2,423 |
| Lupron Depot | 98 | $506,263 | $5,166 |
| Tagrisso | 31 | $493,799 | $15,929 |
| Verzenio | 34 | $448,076 | $13,179 |
| Lynparza | 33 | $364,117 | $11,034 |
| Somatuline Depot | 39 | $358,176 | $9,184 |
| Keytruda | 32 | $322,158 | $10,067 |
| Cabometyx | 15 | $309,630 | $20,642 |
| Avastin | 65 | $306,606 | $4,717 |
| Pomalyst | 16 | $291,133 | $18,196 |
| Lenvima | 15 | $284,666 | $18,978 |
| Tecentriq | 26 | $250,419 | $9,632 |
| Yervoy | 17 | $238,531 | $14,031 |
| Venclexta | 22 | $206,116 | $9,369 |
| Sutent | 25 | $202,535 | $8,101 |
| Imatinib Mesylate | 50 | $192,724 | $3,854 |
| Aranesp | 55 | $163,877 | $2,980 |
| Jakafi | 15 | $159,457 | $10,630 |
| Gilotrif | 12 | $117,793 | $9,816 |
| Nexavar | 11 | $117,589 | $10,690 |
| Abraxane | 15 | $107,761 | $7,184 |
| Empliciti | 13 | $99,073 | $7,621 |
| Tarceva | 12 | $92,755 | $7,730 |
| Gleevec | 16 | $84,563 | $5,285 |
| Velcade | 16 | $81,263 | $5,079 |
| Eliquis | 105 | $61,578 | $586 |
| Fulvestrant | 40 | $60,768 | $1,519 |
| Levoleucovorin | 61 | $56,542 | $927 |
| Doxorubicin Hcl Liposome | 20 | $51,236 | $2,562 |
| Akynzeo | 58 | $40,749 | $703 |
| Xarelto | 51 | $37,714 | $739 |
| Eligard | 23 | $31,510 | $1,370 |
| Creon | 23 | $23,507 | $1,022 |
| Docetaxel | 14 | $22,647 | $1,618 |
| Oxaliplatin | 66 | $21,422 | $325 |
| Entecavir | 12 | $12,830 | $1,069 |
| Palonosetron | 108 | $10,881 | $101 |
| Gemcitabine | 50 | $6,926 | $139 |
| Myrbetriq | 16 | $6,666 | $417 |
| Leucovorin | 36 | $4,183 | $116 |
| Hydroxyurea | 79 | $2,989 | $38 |
| Letrozole | 59 | $2,222 | $38 |
| Budesonide Ec | 13 | $2,183 | $168 |
| Tamoxifen Citrate | 45 | $2,092 | $46 |
| Prednisone | 285 | $1,902 | $7 |
| Paclitaxel | 16 | $1,832 | $114 |
| Bicalutamide | 21 | $1,456 | $69 |
| Mercaptopurine | 21 | $1,437 | $68 |
| Megestrol Acetate | 23 | $1,420 | $62 |
| Dexamethasone | 99 | $1,395 | $14 |
| Acyclovir | 111 | $1,395 | $13 |
| Carboplatin | 26 | $1,211 | $47 |
| Dapsone | 12 | $868 | $72 |
| Ondansetron | 53 | $855 | $16 |
| Prochlorperazine Maleate | 53 | $777 | $15 |
| Anastrozole | 21 | $656 | $31 |
| Sulfamethoxazole-Trimethoprim | 74 | $372 | $5 |
| Warfarin | 22 | $368 | $17 |
| Methotrexate | 16 | $352 | $22 |
| Alendronate | 24 | $339 | $14 |
| Levothyroxine | 12 | $209 | $17 |
| Tamsulosin | 11 | $195 | $18 |
| Famotidine | 12 | $163 | $14 |
| Lisinopril | 27 | $113 | $4 |
| Furosemide | 29 | $85 | $3 |
| Pantoprazole | 12 | $84 | $7 |
| Lorazepam | 17 | $72 | $4 |
| Hydrochlorothiazide | 14 | $35 | $3 |
| Sertraline | 13 | $22 | $2 |
2019: 73 drugs
| Imbruvica | 96 | $1,025,230 | $10,679 |
| Neulasta | 128 | $886,867 | $6,929 |
| Abiraterone Acetate | 138 | $832,121 | $6,030 |
| Revlimid | 49 | $790,312 | $16,129 |
| Xtandi | 54 | $537,096 | $9,946 |
| Lenvima | 27 | $502,718 | $18,619 |
| Lupron Depot | 100 | $470,568 | $4,706 |
| Xgeva | 196 | $466,235 | $2,379 |
| Blincyto | 19 | $463,779 | $24,409 |
| Opdivo | 44 | $388,549 | $8,831 |
| Somatuline Depot | 43 | $359,340 | $8,357 |
| Jevtana | 30 | $347,054 | $11,568 |
| Keytruda | 33 | $328,679 | $9,960 |
| Nexavar | 15 | $294,772 | $19,651 |
| Verzenio | 17 | $244,065 | $14,357 |
| Gleevec | 35 | $238,906 | $6,826 |
| Venclexta | 21 | $224,536 | $10,692 |
| Lonsurf | 17 | $223,894 | $13,170 |
| Tagrisso | 14 | $220,617 | $15,758 |
| Zytiga | 19 | $170,354 | $8,966 |
| Jakafi | 12 | $169,394 | $14,116 |
| Ibrance | 14 | $168,925 | $12,066 |
| Tarceva | 22 | $167,816 | $7,628 |
| Aranesp | 64 | $162,661 | $2,542 |
| Sutent | 15 | $159,526 | $10,635 |
| Lynparza | 11 | $147,911 | $13,446 |
| Avastin | 12 | $143,797 | $11,983 |
| Velcade | 13 | $56,943 | $4,380 |
| Intron A | 14 | $52,270 | $3,734 |
| Imatinib Mesylate | 21 | $52,117 | $2,482 |
| Eliquis | 78 | $40,524 | $520 |
| Xarelto | 48 | $31,316 | $652 |
| Docetaxel | 18 | $31,125 | $1,729 |
| Creon | 29 | $28,996 | $1,000 |
| Fulvestrant | 15 | $25,339 | $1,689 |
| Levoleucovorin | 13 | $12,774 | $983 |
| Palonosetron | 63 | $10,240 | $163 |
| Akynzeo | 13 | $7,380 | $568 |
| Emend | 11 | $4,858 | $442 |
| Gemcitabine | 36 | $4,805 | $133 |
| Letrozole | 89 | $2,759 | $31 |
| Megestrol Acetate | 26 | $2,559 | $98 |
| Hydroxyurea | 81 | $2,482 | $31 |
| Tamoxifen Citrate | 54 | $2,390 | $44 |
| Oxaliplatin | 16 | $1,899 | $119 |
| Ondansetron | 83 | $1,467 | $18 |
| Dexamethasone | 87 | $1,246 | $14 |
| Prednisone | 196 | $1,206 | $6 |
| Doxycycline Hyclate | 22 | $990 | $45 |
| Acyclovir | 69 | $904 | $13 |
| Carboplatin | 17 | $904 | $53 |
| Potassium Chloride | 24 | $902 | $38 |
| Hydrocodone-Acetaminophen | 33 | $872 | $26 |
| Bicalutamide | 30 | $835 | $28 |
| Prochlorperazine Maleate | 70 | $832 | $12 |
| Cisplatin | 18 | $637 | $35 |
| Pantoprazole | 32 | $575 | $18 |
| Anastrozole | 35 | $574 | $16 |
| Oxycodone | 19 | $497 | $26 |
| Irinotecan | 11 | $426 | $39 |
| Diphenoxylate-Atropine | 11 | $369 | $34 |
| Sulfamethoxazole-Trimethoprim | 59 | $331 | $6 |
| Lorazepam | 23 | $320 | $14 |
| Alendronate | 38 | $258 | $7 |
| Sodium Chloride | 22 | $246 | $11 |
| Warfarin | 17 | $228 | $13 |
| Levothyroxine | 14 | $219 | $16 |
| Amlodipine Besylate | 15 | $152 | $10 |
| Furosemide | 18 | $125 | $7 |
| Allopurinol | 12 | $113 | $9 |
| Lisinopril | 19 | $104 | $5 |
| Ciprofloxacin | 15 | $98 | $7 |
| Famotidine | 13 | $80 | $6 |
2018: 52 drugs
| Imbruvica | 102 | $977,463 | $9,583 |
| Neulasta | 116 | $741,629 | $6,393 |
| Revlimid | 45 | $685,354 | $15,230 |
| Xgeva | 221 | $512,561 | $2,319 |
| Zytiga | 46 | $484,502 | $10,533 |
| Ibrance | 33 | $382,891 | $11,603 |
| Xtandi | 39 | $367,667 | $9,427 |
| Somatuline Depot | 47 | $353,545 | $7,522 |
| Lupron Depot | 79 | $347,975 | $4,405 |
| Nexavar | 20 | $332,739 | $16,637 |
| Lenvima | 17 | $300,177 | $17,657 |
| Gleevec | 37 | $264,868 | $7,159 |
| Tarceva | 31 | $249,307 | $8,042 |
| Keytruda | 18 | $176,515 | $9,806 |
| Afinitor | 11 | $171,817 | $15,620 |
| Aranesp | 52 | $158,556 | $3,049 |
| Opdivo | 13 | $136,280 | $10,483 |
| Imatinib Mesylate | 28 | $136,192 | $4,864 |
| Intron A | 20 | $62,852 | $3,143 |
| Velcade | 11 | $41,094 | $3,736 |
| Faslodex | 15 | $33,418 | $2,228 |
| Eliquis | 57 | $24,023 | $421 |
| Xarelto | 33 | $20,738 | $628 |
| Creon | 16 | $9,091 | $568 |
| Letrozole | 146 | $3,628 | $25 |
| Hydroxyurea | 96 | $2,794 | $29 |
| Tamoxifen Citrate | 61 | $1,935 | $32 |
| Anagrelide | 21 | $1,345 | $64 |
| Megestrol Acetate | 21 | $1,324 | $63 |
| Doxycycline Hyclate | 26 | $1,275 | $49 |
| Bicalutamide | 23 | $1,122 | $49 |
| Acyclovir | 70 | $841 | $12 |
| Methotrexate | 14 | $835 | $60 |
| Ondansetron | 49 | $756 | $15 |
| Prednisone | 104 | $659 | $6 |
| Dexamethasone | 87 | $611 | $7 |
| Oxycodone | 15 | $496 | $33 |
| Prochlorperazine Maleate | 74 | $476 | $6 |
| Hydrocodone-Acetaminophen | 18 | $438 | $24 |
| Warfarin | 42 | $403 | $10 |
| Pantoprazole | 31 | $384 | $12 |
| Lorazepam | 33 | $378 | $11 |
| Sulfamethoxazole-Trimethoprim | 68 | $350 | $5 |
| Anastrozole | 26 | $273 | $10 |
| Ondansetron Odt | 12 | $231 | $19 |
| Alendronate | 44 | $203 | $5 |
| Allopurinol | 11 | $156 | $14 |
| Levothyroxine | 12 | $142 | $12 |
| Tamsulosin | 11 | $68 | $6 |
| Furosemide | 22 | $68 | $3 |
| Metoprolol | 11 | $34 | $3 |
| Zolpidem | 12 | $22 | $2 |
2017: 58 drugs
| Neulasta | 130 | $764,290 | $5,879 |
| Nexavar | 61 | $699,651 | $11,470 |
| Imbruvica | 83 | $685,153 | $8,255 |
| Xgeva | 194 | $419,483 | $2,162 |
| Revlimid | 26 | $353,814 | $13,608 |
| Gleevec | 41 | $305,489 | $7,451 |
| Lupron Depot | 69 | $269,919 | $3,912 |
| Xtandi | 33 | $268,504 | $8,136 |
| Zytiga | 25 | $235,902 | $9,436 |
| Somatuline Depot | 32 | $216,796 | $6,775 |
| Afinitor | 15 | $206,354 | $13,757 |
| Sutent | 21 | $182,726 | $8,701 |
| Tarceva | 19 | $143,116 | $7,532 |
| Aranesp | 54 | $141,853 | $2,627 |
| Lonsurf | 26 | $129,666 | $4,987 |
| Jakafi | 18 | $124,125 | $6,896 |
| Imatinib Mesylate | 22 | $109,558 | $4,980 |
| Intron A | 15 | $46,299 | $3,087 |
| Xarelto | 46 | $22,429 | $488 |
| Eliquis | 38 | $15,995 | $421 |
| Akynzeo | 12 | $13,452 | $1,121 |
| Anagrelide | 32 | $3,074 | $96 |
| Letrozole | 106 | $2,802 | $26 |
| Hydroxyurea | 96 | $2,035 | $21 |
| Bicalutamide | 38 | $1,712 | $45 |
| Tamoxifen Citrate | 65 | $1,629 | $25 |
| Ondansetron | 55 | $926 | $17 |
| Methotrexate | 15 | $895 | $60 |
| Megestrol Acetate | 19 | $820 | $43 |
| Dapsone | 12 | $692 | $58 |
| Oxycodone | 19 | $681 | $36 |
| Morphine Sulfate Er | 18 | $660 | $37 |
| Fluorouracil | 12 | $648 | $54 |
| Acyclovir | 64 | $615 | $10 |
| Prochlorperazine Maleate | 76 | $510 | $7 |
| Ceftriaxone | 11 | $449 | $41 |
| Dexamethasone | 120 | $424 | $4 |
| Hydrocodone-Acetaminophen | 31 | $418 | $13 |
| Prednisone | 75 | $401 | $5 |
| Ondansetron Odt | 35 | $363 | $10 |
| Pantoprazole | 29 | $347 | $12 |
| Famotidine | 13 | $337 | $26 |
| Ciprofloxacin | 19 | $305 | $16 |
| Diphenoxylate-Atropine | 11 | $298 | $27 |
| Sulfamethoxazole-Trimethoprim | 64 | $258 | $4 |
| Lorazepam | 51 | $250 | $5 |
| Lisinopril | 36 | $224 | $6 |
| Sodium Chloride | 22 | $223 | $10 |
| Zolpidem | 19 | $199 | $10 |
| Doxycycline Hyclate | 12 | $196 | $16 |
| Warfarin | 19 | $185 | $10 |
| Amlodipine Besylate | 23 | $181 | $8 |
| Methylprednisolone | 15 | $126 | $8 |
| Tamsulosin | 11 | $108 | $10 |
| Anastrozole | 14 | $100 | $7 |
| Alendronate | 18 | $94 | $5 |
| Furosemide | 26 | $84 | $3 |
| Metoprolol | 14 | $66 | $5 |
2016: 50 drugs
| Imbruvica | 73 | $541,855 | $7,423 |
| Nexavar | 51 | $516,589 | $10,129 |
| Xtandi | 67 | $494,815 | $7,385 |
| Gleevec | 46 | $421,266 | $9,158 |
| Revlimid | 35 | $308,089 | $8,803 |
| Neulasta | 51 | $272,077 | $5,335 |
| Zytiga | 30 | $258,299 | $8,610 |
| Afinitor | 21 | $248,930 | $11,854 |
| Lonsurf | 34 | $234,161 | $6,887 |
| Xgeva | 111 | $224,156 | $2,019 |
| Lupron Depot | 50 | $181,194 | $3,624 |
| Tarceva | 19 | $120,693 | $6,352 |
| Jakafi | 20 | $115,328 | $5,766 |
| Imatinib Mesylate | 19 | $95,681 | $5,036 |
| Aranesp | 27 | $85,332 | $3,160 |
| Intron A | 13 | $37,831 | $2,910 |
| Xarelto | 70 | $30,814 | $440 |
| Tasigna | 11 | $29,284 | $2,662 |
| Entecavir | 15 | $13,047 | $870 |
| Exemestane | 20 | $4,373 | $219 |
| Anagrelide | 38 | $3,121 | $82 |
| Bicalutamide | 40 | $1,732 | $43 |
| Letrozole | 92 | $1,732 | $19 |
| Hydroxyurea | 86 | $1,720 | $20 |
| Tamoxifen Citrate | 54 | $1,644 | $30 |
| Megestrol Acetate | 18 | $856 | $48 |
| Dapsone | 14 | $852 | $61 |
| Hydrocodone-Acetaminophen | 21 | $814 | $39 |
| Ondansetron | 65 | $800 | $12 |
| Ondansetron Odt | 34 | $716 | $21 |
| Doxycycline Hyclate | 12 | $608 | $51 |
| Prochlorperazine Maleate | 61 | $590 | $10 |
| Dexamethasone | 95 | $443 | $5 |
| Acyclovir | 30 | $409 | $14 |
| Lidocaine-Prilocaine | 11 | $364 | $33 |
| Famotidine | 15 | $354 | $24 |
| Prednisone | 76 | $320 | $4 |
| Warfarin | 33 | $298 | $9 |
| Pantoprazole | 29 | $297 | $10 |
| Oxycodone | 12 | $285 | $24 |
| Methylprednisolone | 21 | $269 | $13 |
| Sulfamethoxazole-Trimethoprim | 50 | $245 | $5 |
| Zolpidem | 12 | $208 | $17 |
| Lorazepam | 38 | $182 | $5 |
| Metoprolol | 18 | $100 | $6 |
| Anastrozole | 11 | $76 | $7 |
| Amlodipine Besylate | 16 | $55 | $3 |
| Alendronate | 12 | $44 | $4 |
| Furosemide | 18 | $39 | $2 |
| Hydrochlorothiazide | 13 | $34 | $3 |
2015: 43 drugs
| Xtandi | 86 | $640,169 | $7,444 |
| Revlimid | 54 | $550,426 | $10,193 |
| Zytiga | 59 | $457,272 | $7,750 |
| Gleevec | 34 | $363,056 | $10,678 |
| Jakafi | 36 | $236,570 | $6,571 |
| Neulasta | 41 | $224,720 | $5,481 |
| Imbruvica | 37 | $222,783 | $6,021 |
| Xgeva | 111 | $209,394 | $1,886 |
| Nexavar | 20 | $204,280 | $10,214 |
| Lupron Depot | 53 | $184,619 | $3,483 |
| Aranesp | 30 | $113,478 | $3,783 |
| Tarceva | 19 | $113,017 | $5,948 |
| Intron A | 13 | $34,074 | $2,621 |
| Tasigna | 13 | $31,778 | $2,444 |
| Xarelto | 83 | $29,107 | $351 |
| Anagrelide | 15 | $1,783 | $119 |
| Tamoxifen Citrate | 47 | $1,599 | $34 |
| Hydroxyurea | 57 | $1,394 | $24 |
| Bicalutamide | 24 | $1,347 | $56 |
| Letrozole | 87 | $1,323 | $15 |
| Doxycycline Hyclate | 15 | $1,182 | $79 |
| Megestrol Acetate | 25 | $633 | $25 |
| Ondansetron | 38 | $612 | $16 |
| Oxycodone | 23 | $607 | $26 |
| Prednisone | 88 | $534 | $6 |
| Prochlorperazine Maleate | 57 | $385 | $7 |
| Dexamethasone | 47 | $307 | $7 |
| Warfarin | 23 | $225 | $10 |
| Diphenoxylate-Atropine | 12 | $224 | $19 |
| Zolpidem | 13 | $212 | $16 |
| Hydrocodone-Acetaminophen | 12 | $207 | $17 |
| Pantoprazole | 16 | $191 | $12 |
| Lorazepam | 31 | $145 | $5 |
| Lisinopril | 13 | $143 | $11 |
| Acyclovir | 16 | $127 | $8 |
| Amlodipine Besylate | 18 | $125 | $7 |
| Sulfamethoxazole-Trimethoprim | 17 | $118 | $7 |
| Potassium Chloride | 12 | $106 | $9 |
| Ciprofloxacin | 14 | $91 | $7 |
| Anastrozole | 12 | $89 | $7 |
| Metoprolol | 13 | $85 | $7 |
| Losartan | 12 | $46 | $4 |
| Hydrochlorothiazide | 17 | $30 | $2 |
2014: 43 drugs
| Zytiga | 121 | $832,363 | $6,879 |
| Revlimid | 51 | $489,070 | $9,590 |
| Nexavar | 27 | $237,199 | $8,785 |
| Gleevec | 17 | $205,191 | $12,070 |
| Xtandi | 28 | $190,730 | $6,812 |
| Imbruvica | 20 | $149,967 | $7,498 |
| Xgeva | 74 | $133,443 | $1,803 |
| Jakafi | 17 | $132,260 | $7,780 |
| Neulasta | 21 | $124,583 | $5,933 |
| Lupron Depot | 32 | $101,608 | $3,175 |
| Tarceva | 12 | $77,131 | $6,428 |
| Aranesp | 13 | $47,407 | $3,647 |
| Intron A | 13 | $17,659 | $1,358 |
| Xarelto | 57 | $17,221 | $302 |
| Doxycycline Hyclate | 21 | $2,852 | $136 |
| Bicalutamide | 37 | $2,095 | $57 |
| Tamoxifen Citrate | 60 | $1,808 | $30 |
| Letrozole | 77 | $1,712 | $22 |
| Anagrelide | 23 | $1,609 | $70 |
| Hydroxyurea | 42 | $881 | $21 |
| Hydrocodone-Acetaminophen | 28 | $863 | $31 |
| Megestrol Acetate | 13 | $732 | $56 |
| Prednisone | 124 | $713 | $6 |
| Oxycodone | 24 | $656 | $27 |
| Anastrozole | 16 | $505 | $32 |
| Ondansetron | 36 | $429 | $12 |
| Warfarin | 45 | $424 | $9 |
| Lorazepam | 62 | $376 | $6 |
| Dexamethasone | 56 | $320 | $6 |
| Prochlorperazine Maleate | 50 | $304 | $6 |
| Lidocaine-Prilocaine | 13 | $280 | $22 |
| Acyclovir | 12 | $175 | $15 |
| Lisinopril | 22 | $171 | $8 |
| Mirtazapine | 14 | $151 | $11 |
| Omeprazole | 16 | $147 | $9 |
| Pantoprazole | 11 | $140 | $13 |
| Losartan | 13 | $114 | $9 |
| Sulfamethoxazole-Trimethoprim | 19 | $102 | $5 |
| Furosemide | 17 | $91 | $5 |
| Terazosin | 11 | $86 | $8 |
| Allopurinol | 13 | $62 | $5 |
| Alendronate | 13 | $59 | $5 |
| Hydrochlorothiazide | 12 | $29 | $2 |
2013: 38 drugs
| Revlimid | 41 | $404,460 | $9,865 |
| Zytiga | 61 | $391,327 | $6,415 |
| Neulasta | 32 | $171,793 | $5,369 |
| Xtandi | 24 | $162,991 | $6,791 |
| Gleevec | 15 | $154,894 | $10,326 |
| Nilandron | 36 | $82,050 | $2,279 |
| Tarceva | 15 | $77,648 | $5,177 |
| Aranesp | 14 | $47,079 | $3,363 |
| Xgeva | 12 | $20,682 | $1,723 |
| Baraclude | 12 | $12,643 | $1,054 |
| Xarelto | 21 | $6,465 | $308 |
| Letrozole | 80 | $3,556 | $44 |
| Anagrelide | 38 | $2,815 | $74 |
| Bicalutamide | 28 | $2,235 | $80 |
| Hydroxyurea | 51 | $1,626 | $32 |
| Hydrocodone-Acetaminophen | 34 | $1,569 | $46 |
| Doxycycline Hyclate | 11 | $1,151 | $105 |
| Coumadin | 13 | $1,070 | $82 |
| Tamoxifen Citrate | 40 | $1,059 | $26 |
| Oxycodone | 15 | $858 | $57 |
| Warfarin | 71 | $677 | $10 |
| Megestrol Acetate | 13 | $664 | $51 |
| Anastrozole | 12 | $604 | $50 |
| Ondansetron | 31 | $565 | $18 |
| Morphine Sulfate Er | 12 | $407 | $34 |
| Dexamethasone | 53 | $393 | $7 |
| Acyclovir | 15 | $318 | $21 |
| Prochlorperazine Maleate | 36 | $289 | $8 |
| Potassium Chloride | 11 | $275 | $25 |
| Lorazepam | 47 | $245 | $5 |
| Prednisone | 50 | $195 | $4 |
| Sertraline | 12 | $141 | $12 |
| Terazosin | 11 | $113 | $10 |
| Alendronate | 13 | $109 | $8 |
| Ciprofloxacin | 18 | $90 | $5 |
| Metoprolol | 14 | $74 | $5 |
| Lisinopril | 11 | $54 | $5 |
| Folic Acid | 14 | $43 | $3 |
Money from drug and device companies
$81,979 in 2025
| 2025 | 40 | 127 | $77,053 | $81,979 |
| 2024 | 38 | 116 | $45,690 | $49,173 |
| 2023 | 46 | 159 | $104,726 | $109,130 |
| 2022 | 43 | 192 | $109,918 | $114,495 |
| 2021 | 36 | 169 | $98,347 | $101,933 |
| 2020 | 36 | 112 | $51,757 | $53,805 |
| 2019 | 34 | 291 | $181,250 | $194,278 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Opdivo | $46,675 | 30 payments
|
| Astellas Pharma US | Vyloy | $11,065 | 9 payments
|
| Abbvie | Venclexta | $10,048 | 15 payments
|
| Incyte | Zynyz | $6,993 | 12 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $5,492 | 6 payments
|
| Amgen | Vectibix | $199 | 4 payments
|
See all 127 published payments
| E.R. Squibb & Sons L.L.C. | Travel · 2025-12-15 | Opdivo | $8 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-12-15 | Opdivo | $70 |
| Celgene | Meals · 2025-12-04 | Reblozyl | $25 |
| E.R. Squibb & Sons L.L.C. | Paid to speak or teach · 2025-12-01 | Opdivo | $8,280 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-06 | Opdivo | $105 |
| Servier Pharmaceuticals | Meals · 2025-10-27 | Voranigo | $31 |
| Adc Therapeutics America | Meals · 2025-10-27 | Zynlonta | $35 |
| Secura Bio | Meals · 2025-10-23 | Copiktra | $17 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-10-16 | None | $2,960 |
| Abbvie | Meals · 2025-10-14 | Imbruvica | $19 |
| Incyte | Paid to speak or teach · 2025-10-01 | Zynyz | $3,300 |
| Rigel Pharmaceuticals | Meals · 2025-09-29 | Tavalisse | $16 |
| Merck Sharp & Dohme | Meals · 2025-09-26 | Keytruda | $32 |
| Incyte | Meals · 2025-09-24 | Zynyz | $125 |
| Incyte | Travel · 2025-09-24 | Zynyz | $57 |
| Incyte | Travel · 2025-09-24 | Zynyz | $10 |
| Octapharma USA | Meals · 2025-09-22 | Octagam Immune Globulin (Human) | $38 |
| Genentech USA | Meals · 2025-09-19 | Phesgo | $28 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-09-17 | None | $518 |
| Incyte | Paid to speak or teach · 2025-09-16 | Zynyz | $2,200 |
| GlaxoSmithKline | Meals · 2025-09-15 | Ojjaara | $25 |
| Exelixis | Meals · 2025-09-15 | Cabometyx | $40 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Imfinzi | $32 |
| Incyte | Travel · 2025-09-11 | Zynyz | $20 |
| Incyte | Travel · 2025-09-11 | Zynyz | $10 |
| Incyte | Travel · 2025-09-11 | Zynyz | $8 |
| Incyte | Meals · 2025-09-11 | Zynyz | $138 |
| Astellas Pharma US | Travel · 2025-09-10 | Vyloy | $162 |
| Astellas Pharma US | Meals · 2025-09-10 | Vyloy | $123 |
| Astellas Pharma US | Paid to speak or teach · 2025-09-10 | Vyloy | $4,500 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-08 | Opdivo | $24 |
| Abbvie | Paid to speak or teach · 2025-09-02 | Venclexta | $3,125 |
| Exelixis | Meals · 2025-08-26 | Cabometyx | $29 |
| PharmaEssentia USA | Meals · 2025-08-22 | Besremi | $32 |
| Servier Pharmaceuticals | Meals · 2025-08-15 | Tibsovo | $22 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-08-14 | Opdivo | $158 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-08-14 | Opdivo | $10 |
| Syndax Pharmaceuticals | Meals · 2025-08-14 | None | $30 |
| Syndax Pharmaceuticals | Meals · 2025-08-14 | Revuforj | $27 |
| Abbvie | Meals · 2025-08-13 | Venclexta | $108 |
| Abbvie | Travel · 2025-08-13 | Venclexta | $74 |
| Abbvie | Travel · 2025-08-13 | Venclexta | $10 |
| E.R. Squibb & Sons L.L.C. | Paid to speak or teach · 2025-08-12 | Opdivo | $5,693 |
| E.R. Squibb & Sons L.L.C. | Paid to speak or teach · 2025-08-12 | Opdivo | $9,315 |
| Sobi | Meals · 2025-08-11 | Vonjo | $31 |
| Gilead Sciences | Meals · 2025-08-08 | Trodelvy | $26 |
| Ipsen Biopharmaceuticals | Meals · 2025-07-28 | Onivyde | $32 |
| Astellas Pharma US | Paid to speak or teach · 2025-07-25 | Vyloy | $375 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-24 | None | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-24 | Opdivo | $98 |
| Amgen | Meals · 2025-07-24 | Vectibix | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-22 | Opdivo | $4 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-07-21 | None | $2,070 |
| Coherus Oncology | Meals · 2025-07-21 | Loqtorzi | $34 |
| Incyte | Paid to speak or teach · 2025-07-10 | Zynyz | $825 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-06-27 | Nubeqa | $1,218 |
| GlaxoSmithKline | Meals · 2025-06-23 | Jemperli | $26 |
| Karyopharm Therapeutics | Meals · 2025-06-20 | Xpovio | $28 |
| Astellas Pharma US | Meals · 2025-06-19 | Vyloy | $125 |
| Astellas Pharma US | Paid to speak or teach · 2025-06-19 | Vyloy | $4,500 |
| Astellas Pharma US | Travel · 2025-06-19 | Vyloy | $130 |
| Aveo Pharmaceuticals | Meals · 2025-06-16 | Fotivda | $25 |
| Blueprint Medicines | Meals · 2025-06-13 | Ayvakit | $45 |
| Celgene | Meals · 2025-06-03 | Reblozyl | $14 |
| Kyowa Kirin | Meals · 2025-06-02 | Poteligeo | $23 |
| Amgen | Meals · 2025-05-31 | Vectibix | $58 |
| Amgen | Meals · 2025-05-31 | Vectibix | $101 |
| Incyte | Paid to speak or teach · 2025-05-29 | Zynyz | $275 |
| Pfizer | Meals · 2025-05-27 | Xtandi | $29 |
| Jazz Pharmaceuticals | Meals · 2025-05-23 | Ziihera | $40 |
| E.R. Squibb & Sons L.L.C. | Paid to speak or teach · 2025-05-16 | Opdivo | $7,245 |
| Abbvie | Paid to speak or teach · 2025-05-16 | Venclexta | $3,125 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-05-15 | Opdivo | $8 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-05-15 | Opdivo | $56 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-15 | None | $2,070 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-15 | None | $518 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-15 | None | $2,070 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-15 | None | $518 |
| Deciphera Pharmaceuticals | Meals · 2025-05-09 | Qinlock | $30 |
| Celgene | Meals · 2025-05-08 | Reblozyl | $28 |
| SpringWorks Therapeutics | Meals · 2025-05-05 | Ogsiveo | $41 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-02 | Fruzaqla | $35 |
| Abbvie | Meals · 2025-05-01 | Venclexta | $125 |
| Abbvie | Travel · 2025-05-01 | Venclexta | $70 |
| Abbvie | Travel · 2025-05-01 | Venclexta | $8 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-29 | Opdivo | $121 |
| Incyte | Meals · 2025-04-25 | Monjuvi | $26 |
| Astellas Pharma US | Paid to speak or teach · 2025-04-20 | Vyloy | $1,125 |
| Gilead Sciences | Meals · 2025-04-14 | Trodelvy | $23 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-04-11 | None | $518 |
| Merck Sharp & Dohme | Meals · 2025-04-07 | Welireg | $33 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-04-04 | Opdivo | $435 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-04-01 | None | $518 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-04-01 | None | $518 |
| Celgene | Meals · 2025-03-31 | Reblozyl | $26 |
| Amgen | Meals · 2025-03-26 | Vectibix | $16 |
| Celgene | Meals · 2025-03-24 | Opdivo | $34 |
| Abbvie | Meals · 2025-03-22 | Epkinly | $27 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-03-21 | Nubeqa | $8 |
| Bayer Healthcare Pharmaceuticals | Travel · 2025-03-21 | Nubeqa | $168 |
| Bayer Healthcare Pharmaceuticals | Paid to speak or teach · 2025-03-19 | Nubeqa | $3,959 |
| Abbvie | Paid to speak or teach · 2025-03-18 | Venclexta | $3,125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | Enhertu | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-14 | Stivarga | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-14 | Nubeqa | $116 |
| Pfizer | Meals · 2025-03-07 | Eliquis | $23 |
| Daiichi Sankyo | Meals · 2025-03-03 | Vanflyta | $27 |
| Astellas Pharma US | Meals · 2025-02-28 | Padcev | $26 |
| Taiho Oncology | Meals · 2025-02-27 | Lonsurf | $41 |
| Celgene | Meals · 2025-02-26 | Opdivo | $23 |
| Coherus Oncology | Meals · 2025-02-21 | Loqtorzi | $40 |
| Abbvie | Meals · 2025-02-20 | Venclexta | $147 |
| Abbvie | Travel · 2025-02-20 | Venclexta | $21 |
| Abbvie | Travel · 2025-02-20 | Venclexta | $35 |
| Legend Biotech USA | Meals · 2025-02-18 | Carvykti | $28 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-02-04 | None | $2,590 |
| Abbvie | Meals · 2025-02-04 | Creon | $29 |
| Geron | Meals · 2025-01-27 | Rytelo | $36 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-24 | None | $135 |
| Gilead Sciences | Meals · 2025-01-23 | Trodelvy | $22 |
| Adc Therapeutics America | Meals · 2025-01-21 | Zynlonta | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Opdivo | $30 |
| Merck Sharp & Dohme | Meals · 2025-01-17 | Keytruda | $35 |
| Stemline Therapeutics | Meals · 2025-01-14 | Orserdu | $35 |
| Novartis Pharmaceuticals | Meals · 2025-01-10 | Kisqali | $35 |
| Spectrum Pharmaceuticals | Meals · 2025-01-06 | Rolvedon | $23 |
| BeiGene USA | Meals · 2025-01-03 | Tevimbra | $35 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $49,173
| E.R. Squibb & Sons L.L.C. | Opdivo | $19,836 | 19 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $14,599 | 16 payments
|
| Abbvie | Venclexta | $13,113 | 17 payments
|
| Merck Sharp & Dohme | Keytruda | $126 | 4 payments
|
| Gilead Sciences | None | $100 | 4 payments
|
| Pfizer | Bosulif | $95 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $91 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $90 | 3 payments
|
| Novartis Pharmaceuticals | Fabhalta | $84 | 4 payments
|
| Astellas Pharma US | Xtandi | $63 | 3 payments
|
| Blueprint Medicines | Ayvakit | $61 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $57 | 2 payments
|
| Genentech USA | Lunsumio | $53 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $53 | 2 payments
|
| Genzyme | Sarclisa | $52 | 2 payments
|
| Incyte | Monjuvi | $50 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $46 | 2 payments
|
| Servier Pharmaceuticals | Oncaspar | $44 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $43 | 2 payments
|
| Daiichi Sankyo | Enhertu | $42 | 2 payments
|
| Eisai | Lenvima | $38 | 2 payments
|
| Exelixis | Cabometyx | $36 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $35 | 1 payment
|
| Coherus Biosciences | Udenyca | $34 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $31 | 1 payment
|
| Puma Biotechnology | None | $29 | 1 payment
|
| PharmaEssentia USA | Besremi | $29 | 1 payment
|
| ADC Therapeutics America | None | $28 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $28 | 1 payment
|
| Lilly USA | Jaypirca | $26 | 1 payment
|
| Mirati Therapeutics | Krazati | $23 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $23 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $22 | 1 payment
|
| Celgene | Reblozyl | $21 | 1 payment
|
| Secura Bio | Copiktra | $20 | 1 payment
|
| Janssen Biotech | Tecvayli | $18 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $18 | 1 payment
|
| Pharmacosmos Therapeutics | Cosela | $17 | 1 payment
|
2023: $109,130
| E.R. Squibb & Sons L.L.C. | Opdivo | $60,613 | 39 payments
|
| Lilly USA | Retevmo | $24,854 | 23 payments
|
| AbbVie | Venclexta | $13,170 | 13 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $8,023 | 8 payments
|
| G1 Therapeutics | Cosela | $750 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $181 | 7 payments
|
| Novartis Pharmaceuticals | Piqray | $109 | 4 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $105 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $88 | 3 payments
|
| Astellas Pharma US | Xospata | $70 | 3 payments
|
| Pfizer | Ibrance | $58 | 3 payments
|
| Genentech USA | Lunsumio | $58 | 2 payments
|
| PharmaEssentia USA | Besremi | $57 | 2 payments
|
| Octapharma USA | Panzyga | $55 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $53 | 2 payments
|
| Seagen | Adcetris | $53 | 2 payments
|
| ADC Therapeutics America | None | $51 | 2 payments
|
| Sobi | Doptelet | $50 | 2 payments
|
| Celgene | Reblozyl | $47 | 2 payments
|
| Servier Pharmaceuticals | Oncaspar | $44 | 2 payments
|
| Eisai | Lenvima | $42 | 2 payments
|
| Janssen Biotech | Rybrevant | $42 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $37 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $32 | 1 payment
|
| Exelixis | Cabometyx | $32 | 1 payment
|
| Blueprint Medicines | Ayvakit | $30 | 1 payment
|
| Daiichi Sankyo | Enhertu | $28 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $27 | 1 payment
|
| CTI BioPharma | Vonjo | $25 | 1 payment
|
| Amgen | Kyprolis | $24 | 1 payment
|
| MorphoSys US | Monjuvi | $23 | 1 payment
|
| Taiho Oncology | Lonsurf | $23 | 1 payment
|
| Genzyme | Sarclisa | $23 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $23 | 1 payment
|
| Mirati Therapeutics | Krazati | $22 | 1 payment
|
| Gilead Sciences | Trodelvy | $22 | 1 payment
|
| Kyowa Kirin | Poteligeo | $22 | 1 payment
|
| Puma Biotechnology | None | $21 | 1 payment
|
| Incyte | Monjuvi | $21 | 1 payment
|
| Apellis Pharmaceuticals | None | $20 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $19 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $18 | 1 payment
|
| Secura Bio | Copiktra | $18 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $16 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $16 | 1 payment
|
| GlaxoSmithKline | Zejula | $13 | 1 payment
|
2022: $114,495
| E.R. Squibb & Sons L.L.C. | Opdivo | $57,349 | 58 payments
|
| Lilly USA | Retevmo | $25,073 | 26 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $16,060 | 19 payments
|
| Janssen Biotech | Erleada | $7,649 | 16 payments
|
| Abbvie | Venclexta | $3,307 | 3 payments
|
| Celgene | Reblozyl | $2,145 | 7 payments
|
| G1 Therapeutics | Cosela | $1,519 | 2 payments
|
| Pfizer | Ibrance | $103 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $82 | 4 payments
|
| Astellas Pharma US | Padcev | $79 | 4 payments
|
| GlaxoSmithKline | Zejula | $73 | 3 payments
|
| Amgen | Lumakras | $72 | 3 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $66 | 3 payments
|
| Eisai | Lenvima | $61 | 3 payments
|
| Gilead Sciences | Trodelvy | $59 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $57 | 3 payments
|
| Exelixis | Cabometyx | $54 | 2 payments
|
| Novartis Pharmaceuticals | Promacta | $53 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $47 | 2 payments
|
| Genentech | None | $39 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $34 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $33 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $32 | 2 payments
|
| Puma Biotechnology | Nerlynx | $30 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $29 | 1 payment
|
| BeiGene USA | Brukinsa | $27 | 2 payments
|
| Blueprint Medicines | Ayvakit | $27 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $25 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $25 | 1 payment
|
| Kite Pharma | None | $23 | 1 payment
|
| Genzyme | Sarclisa | $23 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $22 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $22 | 1 payment
|
| Secura Bio | Copiktra | $22 | 1 payment
|
| ADC Therapeutics America | None | $21 | 1 payment
|
| Daiichi Sankyo | Enhertu | $21 | 1 payment
|
| Seagen | Adcetris | $20 | 1 payment
|
| Incyte | Jakafi | $20 | 1 payment
|
| Kyowa Kirin | Poteligeo | $19 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $19 | 1 payment
|
| Clovis Oncology | Rubraca | $18 | 1 payment
|
| Sobi | Doptelet | $18 | 1 payment
|
| Taiho Oncology | Lonsurf | $17 | 1 payment
|
2021: $101,933
| E.R. Squibb & Sons L.L.C. | Opdivo | $61,850 | 43 payments
|
| Lilly USA | Verzenio | $12,242 | 19 payments
|
| Janssen Biotech | Erleada | $8,691 | 17 payments
|
| Amgen | Xgeva | $6,950 | 11 payments
|
| Taiho Oncology | Lonsurf | $4,314 | 7 payments
|
| Helsinn Therapeutics (U.S.) | Truseltiq | $1,950 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $1,864 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $1,435 | 4 payments
|
| AbbVie | Venclexta | $922 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $400 | 1 payment
|
| Pfizer | Inlyta | $317 | 14 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $170 | 10 payments
|
| GlaxoSmithKline | Zejula | $93 | 4 payments
|
| Exelixis | Cabometyx | $93 | 3 payments
|
| Eisai | Lenvima | $64 | 3 payments
|
| Seagen | Tukysa | $53 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $50 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $44 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $41 | 3 payments
|
| Coherus Biosciences | Udenyca | $39 | 1 payment
|
| Servier Pharmaceuticals | Oncaspar | $39 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $30 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $29 | 2 payments
|
| AMAG Pharmaceuticals | Feraheme | $24 | 1 payment
|
| Kite Pharma | None | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cosela | $22 | 1 payment
|
| EMD Serono | None | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
| Genzyme | Libtayo | $21 | 1 payment
|
| Clovis Oncology | Rubraca | $20 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $19 | 1 payment
|
| Incyte | Jakafi | $19 | 1 payment
|
| Epizyme | Tazverik | $18 | 1 payment
|
| Astellas Pharma US | Xtandi | $17 | 1 payment
|
| Acrotech Biopharma | Folotyn | $15 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $53,805
| E.R. Squibb & Sons L.L.C. | Opdivo | $24,067 | 24 payments
|
| Lilly USA | Verzenio | $5,642 | 5 payments
|
| Eisai | Lenvima | $5,601 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $5,592 | 3 payments
|
| Taiho Oncology | Lonsurf | $5,468 | 6 payments
|
| Exelixis | Cabometyx | $2,114 | 8 payments
|
| Genentech USA | Tecentriq | $1,844 | 2 payments
|
| AstraZeneca UK | None | $1,370 | 1 payment
|
| Janssen Biotech | Erleada | $599 | 11 payments
|
| Deciphera Pharmaceuticals | Qinlock | $400 | 1 payment
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $258 | 1 payment
|
| Pfizer | Inlyta | $125 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $80 | 4 payments
|
| GlaxoSmithKline | Blenrep | $63 | 2 payments
|
| Seagen | Adcetris | $55 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $53 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $41 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $40 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $30 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $30 | 1 payment
|
| Epizyme | Tazverik | $25 | 1 payment
|
| Astellas Pharma US | Padcev | $25 | 1 payment
|
| Genzyme | Jevtana | $24 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $24 | 1 payment
|
| Allergan | Zenpep | $23 | 1 payment
|
| Array Biopharma | Braftovi | $22 | 1 payment
|
| Blueprint Medicines | Ayvakit | $22 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $22 | 1 payment
|
| EMD Serono | Bavencio | $21 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $21 | 1 payment
|
| Amgen | Neulasta | $20 | 1 payment
|
| Mylan Institutional | Ogivri | $20 | 1 payment
|
| Incyte | Jakafi | $20 | 1 payment
|
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
| Aurobindo Pharma USA | Beleodaq | $15 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $14 | 1 payment
|
2019: $194,278
| Lilly USA | Verzenio | $37,455 | 41 payments
|
| Exelixis | Cabometyx | $36,717 | 42 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $35,317 | 41 payments
|
| Eisai | Lenvima | $17,107 | 19 payments
|
| AbbVie | Venclexta | $17,032 | 16 payments
|
| Janssen Biotech | Erleada | $15,611 | 22 payments
|
| Amgen | Xgeva | $14,223 | 29 payments
|
| Astellas Pharma US | Xtandi | $12,676 | 22 payments
|
| Pfizer | Xtandi | $6,299 | 17 payments
|
| Taiho Oncology | Lonsurf | $1,050 | 1 payment
|
| Genentech USA | Gazyva | $125 | 6 payments
|
| Genzyme | Tumor Lysis Syndrome - Disease | $82 | 4 payments
|
| Novartis Pharmaceuticals | Tasigna | $76 | 4 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $58 | 3 payments
|
| Heron Therapeutics | Cinvanti | $45 | 2 payments
|
| Clovis Oncology | Rubraca | $35 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $35 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $25 | 1 payment
|
| Seattle Genetics | None | $24 | 1 payment
|
| Celgene | Revlimid | $23 | 1 payment
|
| Servier Pharmaceuticals | Oncaspar | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $22 | 1 payment
|
| Puma Biotechnology | Nerlynx | $21 | 1 payment
|
| Daiichi Sankyo | Injectafer | $21 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $20 | 1 payment
|
| Tesaro | Zejula | $20 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| Incyte | Jakafi | $18 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $17 | 1 payment
|
| Array BioPharma | Braftovi | $17 | 1 payment
|
| Spectrum Pharmaceuticals | Folotyn | $16 | 1 payment
|
| EMD Serono | Bavencio | $16 | 1 payment
|
| Verastem | Copiktra | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eisai Inc. · An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma · 2019 | Their institution | $657,536 |
| AstraZeneca Pharmaceuticals LP · A Randomized 2-Cohort Double-Blind Placebo-Controlled Phase III Study of Azd5305 in Combination With Physicians Choice New Hormonal Agents in Patients With Hrrm and Non-Hrrm Metastatic Castration-Sensitive Prostate Cancer Evopar-Prostate01 · 2025 | Their institution | $203,745 |
| Eisai Inc. · An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma · 2020 | Their institution | $114,199 |
| Novartis Pharmaceuticals Corporation · Modular Phase 2 Study To Link Combination Immune Therapy To Patients With Advanced Solid and Hematologic Malignancies Module 1 Pdr001 Plus Lag525 for Patients With Advanced Malignancies · 2019 | Their institution | $77,937 |
| E.R. Squibb & Sons, L.L.C. · Ph III Registrational Study in 1l Hcc Nivo Monotherapy · 2019 | Their institution | $72,756 |
| Novartis Pharmaceuticals Corporation · Modular Phase 2 Study To Link Combination Immune Therapy To Patients With Advanced Solid and Hematologic Malignancies Module 1 Pdr001 Plus Lag525 for Patients With Advanced Malignancies · 2020 | Their institution | $59,571 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2024 | Their institution | $59,447 |
| Genentech, Inc. · A Phase III Open Label Randomized Study Evaluating the Efficacy and Safety of Atezolizumab in Comb · 2019 | Their institution | $58,613 |
| E.R. Squibb & Sons, L.L.C. · Testing the Addition of An Idh2 Inhibitor, Enasidenib, To Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (Mds) With Idh2 Mutation (A Myelomatch Treatment Trial) · 2025 | Their institution | $53,312 |
| Genentech, Inc. · Abiraterone Plus Gdc 0068 Or Gdc 0980 in Crpc · 2021 | Their institution | $47,016 |
| Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2019 | Their institution | $45,179 |
| E.R. Squibb & Sons, L.L.C. · Ph Iib 2l Bladder Registrational · 2020 | Their institution | $44,471 |
| E.R. Squibb & Sons, L.L.C. · Ph III Registrational Study in 1l Hcc Nivo Monotherapy · 2020 | Their institution | $42,077 |
| Genentech, Inc. · Gdc0068 Comb W Taxotere Or Folfox · 2020 | Their institution | $39,796 |
| Merck Sharp & Dohme Corporation · A Phase 3 Multicenter, Randomized, Double-Blinded, Active-Controlled, Clinical Study To Evaluate the Safety and Efficacy of Lenvatinib E7080,Mk-7902 in Combination With Pembrolizumab Mk-3475 Versus Lenvatinib in First-Line Therapy of Participants With Advanced Hepatocellular Carcinoma Leap-002 · 2019 | Their institution | $35,615 |
| Genentech, Inc. · Gdc0068 Comb W Taxotere Or Folfox · 2019 | Their institution | $33,949 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blind, Controlled Study of Cabozantinib Xl184 Vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib · 2021 | Their institution | $33,899 |
| Merck Sharp & Dohme Corporation · Phase Ib/II Trial of Pembrolizumab (Mk-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) (Keynote-365) · 2019 | Their institution | $32,492 |
| Genentech, Inc. · A Phase III of Atezolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer · 2019 | Their institution | $31,582 |
| Eisai Inc. · An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma · 2021 | Their institution | $30,201 |
| Merck Sharp & Dohme Corporation · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2021 | Their institution | $29,297 |
| Genentech, Inc. · A Phase III of Atezolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer · 2020 | Their institution | $27,598 |
| Eisai Inc. · A Multicenter, Randomized, Open-Label, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma · 2019 | Their institution | $25,641 |
| Merck Sharp & Dohme LLC · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2022 | Their institution | $24,540 |
| Celgene Corporation · A Phase 3, Two-Part, Randomized, Open-Label, Adaptive Study Comparing Bms-986365 Versus Investigators Choice of Therapy Comprising Either Docetaxel Or Second Androgen Receptor Pathway Inhibitor (Arpi), in Participants With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) - Recharge · 2025 | Their institution | $23,750 |
| Merck Sharp & Dohme LLC · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2023 | Their institution | $23,373 |
| Merck Sharp & Dohme LLC · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2025 | Their institution | $22,662 |
| Genentech, Inc. · Gdc0068 Comb W Taxotere Or Folfox · 2021 | Their institution | $21,631 |
| E.R. Squibb & Sons, L.L.C. · Phii 1l Hcc Rela+Nivo+Bev Vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-Controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma · 2023 | Their institution | $17,180 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025 | Their institution | $17,100 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Two-Part, Randomized, Open-Label, Adaptive Study Comparing Bms-986365 Versus Investigators Choice of Therapy Comprising Either Docetaxel Or Second Androgen Receptor Pathway Inhibitor (Arpi), in Participants With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) - Recharge · 2025 | Their institution | $17,049 |
| Merck Sharp & Dohme LLC · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2024 | Their institution | $16,898 |
| ABBVIE INC. · Study To Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma · 2024 | Their institution | $16,569 |
| AstraZeneca Pharmaceuticals LP · A Phase 2, Open-Label, Randomized, Multicenter, Platform Study of Novel Oncology Therapies in Combination With Adjuvant Chemotherapy in High-Risk Microsatellite-Stable Colorectal Cancer (Columbia-2) · 2020 | Their institution | $16,388 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (Topaz-1) · 2020 | Their institution | $16,299 |
| Gilead Sciences, Inc. · A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gs-5745 As Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors · 2019 | Their institution | $16,189 |
| Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Mrtx849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With Kras G12c Mutation With Disease Progression on Or After Standard First-Line Therapy · 2023 | Their institution | $15,707 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blind, Controlled Study of Cabozantinib Xl184 Vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib · 2019 | Their institution | $14,705 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gastric Nivo Ipi Vs Nivo Ct Vs Ct · 2019 | Their institution | $13,967 |
| Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Mrtx849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With Kras G12c Mutation With Disease Progression on Or After Standard First-Line Therapy · 2024 | Their institution | $12,974 |
| Genentech, Inc. · A Phase III Open Label Randomized Study Evaluating the Efficacy and Safety of Atezolizumab in Comb · 2020 | Their institution | $12,902 |
| Genentech, Inc. · Abiraterone Plus Gdc 0068 Or Gdc 0980 in Crpc · 2020 | Their institution | $12,000 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2020 | Their institution | $11,546 |
| ABBVIE INC. · Study To Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma · 2023 | Their institution | $11,500 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2020 | Their institution | $11,403 |
| ABBVIE INC. · Study To Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma · 2025 | Their institution | $10,757 |
| Genentech, Inc. · Abiraterone Plus Gdc 0068 Or Gdc 0980 in Crpc · 2022 | Their institution | $9,525 |
| Exelixis Inc. · A Randomized, Controlled Phase 3 Study of Cabozantinib Xl184 in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy · 2019 | Their institution | $8,550 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2019 | Their institution | $8,349 |
| Genentech, Inc. · Abiraterone Plus Gdc 0068 Or Gdc 0980 in Crpc · 2019 | Their institution | $8,319 |
| Halozyme Inc · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Pegylated Recombinant Human Hyaluronidase (Pegph20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit · 2019 | Their institution | $7,981 |
| Exelixis Inc. · A Randomized, Controlled Phase 3 Study of Cabozantinib Xl184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy · 2020 | Their institution | $7,503 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study Adj Gej & Esoph US Eu Mono · 2019 | Their institution | $6,828 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2019 | Their institution | $6,600 |
| Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2020 | Their institution | $5,674 |
| Genentech, Inc. · Abiraterone Plus Gdc 0068 Or Gdc 0980 in Crpc · 2023 | Their institution | $5,572 |
| Merck Sharp & Dohme Corporation · Phase Ib,II Trial of Pembrolizumab Mk-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer Mcrpc Keynote-365 · 2019 | Their institution | $5,381 |
| QED Therapeutics, Inc. · Phase 3 Study of Bgj398 (Oral Infigratinib) in First Line Cholangiocarcinoma With Fgfr2 Gene Fusions/Translocations · 2021 | Their institution | $4,666 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study Adj Gej & Esoph US Eu Mono - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab Or Placebo in Subjects With Resected Esophageal Or Gastroesophageal Junction Cancer · 2022 | Their institution | $4,590 |
| Genentech, Inc. · Phase III Ipatasertib Plus Abirateron in Mcrpc 1st Line · 2021 | Their institution | $4,163 |
| AstraZeneca Pharmaceuticals LP · Durvalumab Or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer Topaz-1 · 2021 | Their institution | $4,040 |
| Exelixis Inc. · A Randomized, Controlled Phase 3 Study of Cabozantinib Xl184 in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy · 2021 | Their institution | $3,950 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2020 | Their institution | $3,725 |
| AstraZeneca UK Limited · A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib and Docetaxel Versus Placebo and Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2022 | Their institution | $3,500 |
| E.R. Squibb & Sons, L.L.C. · Ph Iib 2l Bladder Registrational · 2021 | Their institution | $3,308 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2021 | Their institution | $2,789 |
| Genentech, Inc. · A Phase III of Atezolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer · 2021 | Their institution | $2,375 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2021 | Their institution | $2,325 |
| Taiho Oncology, Inc. · Taiho Tas 102 Gastric Cancer Tags · 2019 | Their institution | $2,133 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study Adj Gej & Esoph US Eu Mono · 2020 | Their institution | $2,072 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Bladder Nivo Mono · 2020 | Their institution | $1,856 |
| Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2022 | Their institution | $1,780 |
| Genentech, Inc. · A Phase III Open Label Randomized Study Evaluating the Efficacy and Safety of Atezolizumab in Comb · 2022 | Their institution | $1,705 |
| Eli Lilly and Company · Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care -Bsc- Versus Placebo and Bsc As Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein -Afp- Following First Line Therapy With Sorafenib · 2021 | Their institution | $1,670 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc (Mono Vs Placebo) · 2024 | Their institution | $1,650 |
| Incyte Corporation · A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome · 2020 | Their institution | $1,500 |
| Genentech, Inc. · A Phase III Open Label Randomized Study Evaluating the Efficacy and Safety of Atezolizumab in Comb · 2021 | Their institution | $1,100 |
| E.R. Squibb & Sons, L.L.C. · Ph III Registrational Study in 1l Hcc Nivo Monotherapy · 2021 | Their institution | $1,080 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2023 | Their institution | $1,000 |
| E.R. Squibb & Sons, L.L.C. · Ph Iib 2l Bladder Registrational · 2019 | Their institution | $911 |
| Incyte Corporation · A Phase 2, Open Label, Single Arm, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Advancedmetastatic Or Surgically Unresectable Cholangiocarcinoma Including Fgfr2 Translocations Who Failed Previous Therapy · 2019 | Their institution | $900 |
| ABBVIE INC. · Study To Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma · 2024 | Their institution | $844 |
| E.R. Squibb & Sons, L.L.C. · Phii 1l Hcc Rela+Nivo+Bev Vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-Controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma · 2022 | Their institution | $575 |
| Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Gene Deficiency (Triton2) · 2022 | Their institution | $520 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma After Curative Hepatic Resection Or Ablation · 2025 | Their institution | $495 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2022 | Their institution | $398 |
| F. Hoffmann-La Roche AG · A Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of Gdc-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, Or Enzalutamide in Patients With Advanced Solid Tumors · 2020 | This clinician | $237 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2019 | Their institution | $203 |
| ABBVIE INC. · M24-147 - Study To Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma · 2025 | Their institution | $129 |
| Merck Sharp & Dohme LLC · A Phase III Study of Pomalidomide and Dexamethasone With Or Without Pembrolizumab in Refractory Or Relapsed and Refractory Multiple Myeloma Rrmm. · 2022 | Their institution | $22 |
| Merck Sharp & Dohme LLC · A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With Or Without Pembrolizumab Mk3475 in Newly Diagnosed and Treatment Naive Multiple Myeloma Keynote 185. · 2023 | Their institution | $4 |
| Merck Sharp & Dohme LLC · A Phase III Study of Pomalidomide and Dexamethasone With Or Without Pembrolizumab in Refractory Or Relapsed and Refractory Multiple Myeloma Rrmm. · 2023 | Their institution | $0 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013086420
- Licence
- CA G72619California G72619: Current · expires 2027-07-31
- Trained
- Tufts University School of Medicine, 1990 · 36 years ago
- Group
- Sutter Bay Medical Foundation · Pacific Hematology Oncology Assoc.
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA YYY49266Y
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 2100 Webster Street Suite 225, San Francisco, CA, 94115
- NPI first listed
- 2006-11-07
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.